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1Abstract
Malignant pleural mesothelioma (MPM) is a form of neoplasia of the cells
covering the surface of the pleural cavity. The only confirmed etiological
factor is asbestos. Treatment of mesothelioma is generally based on surgery,
chemotherapy and/or radiotherapy.
In the last decade, different radiotherapy techniques have become avail-
able for the treatment of MPM. 3D-conformal radiotherapy (3DCRT) using
photons and electrons was the main radiotherapy treatment available until
the beginning of 2000. Since then, intensity modulated radiotherapy (IMRT)
followed by volumetric modulated arc therapy (VMAT) and proton therapy
(PT) have become available. The implementation of these new techniques
for MPM is very challenging due to different reasons. First, the size of the
volume to treat is usually very large, and may go up to six liters. Second,
the doses to be delivered to the target are high and may easily exceed 50 Gy.
Third, the target lies in close proximity to vital and sensitive organs at risk
such as the heart, kidney, liver, lung and spinal cord. Fourth, changes of the
patient’s anatomy and morphology may occur during radiotherapy leading
to a modification of the dose distribution.
In this work, I investigated these new approaches for the treatment of
MPM with radiotherapy. In the first step, I did a plan optimization for IMRT
by looking at the optimal number of beams, field size and beam direction
needed to have the best dose distribution. In a second step, I compared
the results based on the clinical outcome, such as local control, disease free
survival, overall survival and dose distribution to the standard treatment
used, 3DCRT. I showed that IMRT improved the dose conformity but the
overall complication rates remained high. I saw major complications post-
radiotherapy for 22 % of the IMRT patients. In order to improve treatment
quality, I evaluated other treatment techniques, such as VMAT or PT. The
results showed that VMAT as well as PT were both able to reduce the dose
to healthy tissue whilst maintaining high dose conformity when compared to
3DCRT and IMRT.
I demonstrated that IMRT, VMAT and PT were able to achieve higher
tumor conformity which resulted in better tumor control rates compared to
3DCRT. Technically however, I observed that tumor conformity could be
affected by changes of the patient’s anatomy and morphology during pro-
tracted fractionated RT. This was especially the case for MPM patients with
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large air cavities in the hemithorax after removal of the lung. During radio-
therapy, I showed that the volume of the cavity will decrease progressively
over time in an unpredictable way. This cavity will disappear within days to
months and thus will affect surrounding anatomy and modify the dose distri-
bution. This study demonstrated that these modifications were more or less
pronounced depending on the radiotherapy technique used. Modulated pho-
ton radiotherapy techniques appeared to be robust when small anatomical
changes occurred, which was not the case for PT. For PT small changes of tis-
sue density resulted in drastic dose distribution changes. Therefore adaptive
radiotherapy will be required in order to take into account anatomy modifi-
cations. In order to optimize this process, image registration will be required
in order to propagate the structures from one CT to an-other. In order to
perform this step automatically, a colaboration with the Swiss Federal Insti-
tute of Technology Zurich was done to developp a new non-rigid automatic
registration. Therefore, we compared inter- and intraobserver variability to
the automatic resigstration. This study showed that inter- and intraobserver
deviations were greater or similar to the variance of the population formed
by deviations in contouring for the elastic region in a very large portion of
the target volume. Therefore, this non rigid registration could be a big assess
for adaptive RT.
In conclusion, I showed that modulated RT was able to reduce the treat-
ment toxicity in comparison to 3DCRT and enhanced tumor control. The
dose distribution was further improved with VMAT. Nevertheless, no dif-
ference was observed in respect to overall survival due to the high rate of
distant metastasis. PT was able to further reduce the dose to all organs at
risks in comparison to any photon techniques. However, PT was the most
sensitive treatment to modifications of the anatomy, emphasizing the need
for adaptive RT and replanning. A non-rigid registration algorithm was also
developped. Using this tool, efficient adaptive radiotherapy can be realized
by propagating structures of interest between datasets.
3Zusammenfassung
Ein malignes Pleuramesotheliom (MPM) ist eine Form von Neoplasie der
Zellen, welche die Oberfla¨che der Pleura bedeckt. Eine ha¨ufige Ursache hi-
erfu¨r ist Asbest. Die Behandlung von Mesotheliomen basiert in der Regel
auf Chirurgie, Chemotherapie und/oder Strahlentherapie.
Innerhalb der letzten zehn Jahre wurden verschiedene Strahlentherapie-
Techniken fu¨r die Behandlung von MPM verfu¨gbar. Bis ins Jahr 2000 waren
3D-konformale Strahlentherapie (3DCRT) Techniken mit Photonen und
Elektronen die weitverbreitetste Behandlungsmethode in der Strahlenthera-
pie. Mittlerweile sind weitere Techniken wie intensita¨tsmodulierte Strahlen-
therapie (IMRT), volumen-intensita¨tsmodulierte Arc-Therapie (VMAT)
und Protonentherapie (PT) verfu¨gbar geworden. Die Umsetzung dieser
neuen Techniken ist jedoch auf Grund von verschiedenen Gru¨nden sehr
anspruchsvoll. Erstens ist die Gro¨sse des zu behandelten Volumens in der
Regel sehr gross und kann bis zu sechs Liter fassen. Zweitens sind die an
das Zielvolumen verschriebenen Dosen hoch und ko¨nnen leicht mehr als 50
Gy betragen. Drittens befindet sich das Zeilvolumen in der Na¨he essentieller
und empfindlicher Organe wie dem Herzen, der Niere, der Leber, der Lunge
und dem Ru¨ckenmark. Viertens ko¨nnen Vera¨nderungen der Anatomie und
Morphologie des Patienten wa¨hrend der Strahlentherapie auftreten, welche
zu einer modifizierten Dosisverteilung fu¨hren.
In dieser Arbeit, habe ich diese neue Strahlentherapie-Techniken fu¨r
MPM Patienten evaluiert. Im ersten schritt habe ich die Bestrahlung Ge-
ometrie optimiert fu¨r IMRT.
Dann habe ich die IMRT und die 3DCRT verglichen im Bezug auf deren
klinische Ergebnisse, wie z.B. lokale Kontrolle, krankheitsfreies U¨berleben,
Gesamtu¨berleben und Dosisverteilung. Ich habe gezeigt, dass die Dosiskon-
formita¨t durch die IMRT verbessert werden konnte, allerdings blieb die
gesamte Komplikationsrate hoch. Schwerwiegende Post-Radiotherapeutische
Komplikationen wurden in 22 % IMRT Patienten beobachtet. Um die Be-
handlungsqualita¨t zu verbessern haben ich andere Behandlungstechniken,
wie VMAT oder PT ausgewertet. Im Vergleich zu 3DCRT und IMRT waren
VMAT sowie PT beide in der Lage die Dosis auf gesundes Gewebe zu re-
duzieren und dabei die hohe Dosiskonformita¨t beizubehalten.
Ich habe gezeigt, dass IMRT, VMAT und PT in der Lage waren
bessere Tumor-Konformita¨t zu erreichen, was zu besseren Tumorkontroll-
raten gefu¨hrt hat im Vergleich zu 3DCRT. Technisch konnte ich jedoch
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beobachten, dass die Tumor-Konformita¨t bei stark-fraktionierter Strahlen-
therapie durch Vera¨nderungen der Anatomie und Morphologie des Patienten
beeinflusst wird. Dies war insbesondere fu¨r MPM Patienten mit grossem
Hohlraum in der Ha¨mithorax, nach Entfernung der Lunge, der Fall. Das
Volumen des Hohlraums verkleinert sich wa¨hrend der Strahlentherapie in un-
vorhersehbarer Weise, sodass der Hohlraum nach wenigen Tagen bis hin zu
Monaten verwindet. Dies beeinflusst die umliegende Anatomie und vera¨ndert
die Dosisverteilung. Ich zeigte, dass die Auspra¨gung der Vera¨nderungen von
der verwendeten Strahlentherapietechnik abha¨ngt. Die modulierten Photo-
nenstrahlenbehandlungstechniken scheinen gegenu¨ber kleinen anatomischen
Vera¨nderungen robust zu sein, was jedoch fu¨r die PT nicht der Fall war.
Bei der PT fu¨hrten kleine Vera¨nderungen von Gewebedichten zu drastis-
chen Vera¨nderungen in der Dosisverteilung. Wenn die Vorteile der Protonen-
strahlgeometrie Toxizita¨t zu minimieren ausgenutzt werden sollen, wird de-
shalb eine adaptive Strahlentherapie beno¨tigt, um anatomische Vera¨nderun-
gen zu beru¨cksichtigen. Um diesen Prozess zu optimieren ist eine Bildreg-
istrierung erforderlich, damit die Strukturen von einem CT zu einem anderen
u¨bertragen werden ko¨nnen. Hierfu¨r habe ich einen neuen nicht-starren Al-
gorithmus evaluiert.
Zusammenfassend habe ich gezeigt, dass die IMRT im Vergleich zur
3DCRT in der Lage ist die Behandlungstoxizita¨t zu reduzieren. Ausserdem
konnte eine bessere Tumorkontrolle festgestellt werden. Die Dosisverteilung
konnte durch VMAT weiter verbessert werden und PT konnte gegenu¨ber
allen Photonen Techniken die Dosis umliegender Risikoorgane weiter re-
duzieren. Die Behandlung mit PT reagierte allerdings am empfindlichsten
auf Vera¨nderungen der Anatomie, was die Notwendigkeit fu¨r adaptive RT
und Umplanung verdeutlicht. Ein nicht-starrer Registrierung Algorithmus
wurde ebenfalls analysiert. Mit diesem Tool kann eine effiziente adaptive
Strahlentherapie durch die Weitergabe von Strukturen von Interesse real-
isiert werden.
5Re´sume´
Le cancer du me´sothe´liome se de´veloppe dans la majorite´ des cas dans la
re´gion de la ple´vre. L’apparition du me´sothe´liome survient ge´ne´ralement
apre`s exposition a` l’amiante. Ces me´sothe´liomes peuvent eˆtre ope´re´s, traite´s
par la che´motherapie ou la radiothe´rapie. La radiotherapie conformationnelle
(3DCRT) e´tait le principale traitement utilisant des e´lectrons et photons
pour les me´sothe´liomes jusqu’au de´but des anne´es 2000. Durant la dernie`re
de´cennie de nouvelles techniques en radiothe´rapie ont vu le jour pour le
traitement du me´sothe´liome, tel que la radiothe´rapie conformationnelle avec
modulation de l’intensite´ (IMRT), arc the´rapie avec modulation de l’intensite´
(VMAT) et la protonthe´rapie (PT).
L’imple´mentation de ces nouvelles techniques n’est pas aise´e pour les
raisons suivantes: la taille de la re´gion a` traiter est tre`s grande, jusqu’a` 6
litres, la dose a` de´livrer est e´leve´e, de´passant les 50 Gy, les nombreux organes
a` proximite´ de la tumeur et les modifications d’anatomie pouvant survenir
durant le traitement.
Dans ce travail, j’ai e´value´ de nouvelles approches pour la radiotherapie
de patients ayant un cancer du me´sothe´liome. Lors de la premie´re e´tape, j’ai
optimise´ la ge´ome´trie du traitement avec IMRT afin d’optenir la meilleure dis-
tribution de dose possible. Dans un second temps, j’ai compare´ les re´sultats
base´s sur la distribution de la dose, la survie sans maladie et sans progression
de la tumeur ainsi que la survie globale a` la the´rapie standard, 3DCRT. J’ai
pu montre´ que la conformite´ ainsi que l’homoge´ne´ite´ de la dose des patients
traite´ avec IMRT e´taient meilleures. Ne´anmoins, un taux de complications
e´leve´ suite a` la radiation avec 3DCRT et IMRT a` e´te´ observe´. De ce fait,
j’ai e´value´ deux autres techniques, VMAT et PT. Ces deux techniques ont
permis d’ame´liorer la distribution de dose en comparaison a` IMRT et 3DCRT
en diminuant la dose aux tissus sains.
Ces techniques de radiothe´rapies sont capables de produire une grande
conformite´ de dose autour de la re´gion cible. Par contre, j’ai de´montre´ que
cette conformite´ sera affecte´e par une modification de l’anatomie du patient.
Cela est spe´cialement le cas du traitement des me´sothe´liomes ou` une grande
cavite´ d’air peut eˆtre pre´sente apre`s ope´ration. Cette cavite´ d’air va dis-
paraitre en quelques jours a` quelques mois modifiant l’anatomie du patient.
J’ai oberve´ que l’impact sur la distribution de dose sera plus ou moins im-
portante suivant la technique utilise´e. En effet, la conformite´ de la dose sera
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modifie´e dans une moindre mesure avec IMRT et VMAT, alors que la distri-
bution de dose sera drastiquement modifie´e avec PT impliquant la ne´cessite´
de faire de la radiothe´rapie adaptative. Afin d’optimiser le processus de
la radiothe´rapie adaptive, il est ne´cessaire de pouvoir aligner les images.
Pour cela, une colaboration avec l’Ecole Polythechnique Fe´de´rale de Zurich
a e´te´ faite afin de de´velopper un algorithme utilisant une de´formation non-
rigide. Ce nouvel algorithme donne des re´sultats similaire a` la se´gmentation
manuelle, avec l’avantage d’eˆtre automatise´.
En conclusion, j’ai montre´ que les traitements a` modulation d’intensite´
permettent de re´duire la toxicite´ du traitement et d’ame´liorer le controˆle
de la tumeur en comparaison a` 3DCRT. L’ame´lioration du controˆle de la
tumeur n’affecte pas la survie globale du au nombre e´leve´ de me´tastases se
de´veloppant apre`s traitement. Une le´ge´re ame´lioration de la distribution de
dose est observe´e lorsque VMAT est utilise´ au lieu de IMRT. PT est capable
de re´duire drastiquement la dose a` tous les tissus sains par rapport aux
autres techniques. Par contre, PT est la technique la plus affecte´e par une
modification de l’anatomie impliquant la ne´cessite´ de faire de la radiotherapy
adaptive. Pour cela, un algorithme a e´te´ de´veloppe´ qui permet la propagation
automatique de structures d’un CT a` un autre CT.
71 Introduction
1.1 Mesothelioma cancers
Malignant mesothelioma is a form of cancer that occurs in the layer of cells
lining the mesothelium. The mesothelium is a membrane that lines several
cavities including the pleura (thoracic cavity), see Fig. 1.1, peritoneum (gap
between the abdominal wall and abdominal organs) and the pericardium
(lines the heart and the proximal ends of the root of the pulmonary artery,
aorta and vena cava).
Figure 1.1: Pleural mesothelioma primary location is the pleural cavity. The
pleural cavity is the gap between the parietal (outer) pleura attached to the
chest wall and the visceral pleura covering the lung.
The primary location of malignant mesothelioma is in most of the cases
the pleural region but can also occur more rarely in the peritoneal region.
Malignant pleural mesotheliomas are generally confined to the pleural cavity
which is located between the parietal pleura and the visceral pleura, see
Fig. 1.1. After a period of time, typically years, the tumor metastasizes and
progresses through the pleural space, including the chest wall, mediastinum,
diaphragmatic and pericardial surfaces, peritoneum and lymph nodes [1].
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1.2 Epidemiology of malignant pleural
mesothelioma
In at least 80 % of all documented cases, malignant mesothelioma occurs
after exposure to asbestos [2]. Chrysotile, amosite, and crocidolite are the
three main types of asbestos that are correlated with the apparition of MPM.
The risk of developing MPM as the result of occupational exposure to as-
bestos varies in accordance with the type of asbestos exposed to. The risk
is 500 and 100 times more likely when exposed to crocidolite and amosite
respectively than to chrysotile. [3]. Asbestos is considered the main cause of
MPM however around 20 % of mesothelioma patients present no history of
asbestos exposure [4]. However, in individual cases, it is often not clear if an
exposing period was masked by the long latency time. Beside asbestos, other
factors may contribute to mesothelioma. This is the case for young children
with no exposure to asbestos who developed mesothelioma [5].
Since the 1950’s, the number of patients diagnosed with MPM has been
growing. The reason has been linked to the escalation of industrial appli-
cations of asbestos in the Western countries until the 1990’s. Furthermore,
better diagnostic techniques could also account to some extent for the in-
creasing incidence of MPM. Taking into account a latency period of 30 years
or more and the fact that asbestos has been banned in the late 1980’s in
Europe, a peak of incidence with around 9000 victims per year should be
reached in Europe in 2020 [5].
The incidence rate increases with age. Indeed, for men aged between 0
and 54 years, the incidence rate was 0.1 cases per million between 2008 and
2009 in the United States [6]. The incidence rate increases to 2.3 for men
aged between 55 and 64 years and to 7.2 for men aged beween 65 and 74.
This goes on to increase to 15.0 for men aged between 75 and 84 years and
to 21.7 for men above 85 years. For women, the same increase is observed.
The incidence rate goes from 0.1 cases per million for women under 55 years
to 3.0 for women above 85 years. In Europe, the incidence rates are similar
to the United States , see Fig. 1.2. The difference of incidence rate with age
comes mostly from the latency period and the decrease of use of asbestos in
the past 30 years.
The higher incidence rate for men indicates that occupational exposure to
asbestos is more relevant than environmental exposure [5]. Approximately 10
% of the people which have been exposed to a significant amount of asbestos
at work will develop mesothelioma. Nevertheless, environmental exposure
to asbestos has also been reported to have a direct impact on the rate of
patients developing mesothelioma. Indeed, environmental exposure has also
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Figure 1.2: Age-specific mesothelioma mortality rate by age group and gender
between 1994 and 2008 worldwide [7].
been observed in villages in Turkey where natural asbestos was present. In
these villages, the mortality rate increased up to 700 cases per 100 000 people
annually [8]. This was the cause of 44.5 % of all the deaths in these villages.
After banning asbestos from various applications in construction, a new
category of cancerogenes rises: in the past years, nanotubes have been in-
creasingly used in different applications. There are thousands of new mate-
rials which contain carbon nanotubes such as textiles, sports equipment and
electronics. The dimension resemblance between nanotubes and asbestos
has raised the question of the potential health hazards of nanotubes. Stud-
ies performed on mice with an intraperitoneal injection of carbon nanotubes
resulted in inflammations and lesions within the peritoneal region. These
results are similar to seen after asbestos exposure [9]. Therefore, studies hy-
pothesize that long term response after exposure to nanotubes could lead to
mesothelial injury which has been linked to the first stage of mesothelioma.
Therefore, special care has to be taken with the use and fabrication of nan-
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otubes devices. Otherwise a new peak of mesothelioma could appear in 30-40
years.
1.3 Asbestos
Asbestos is a term for six mineral fibers used in industry for their physical
properties. All asbestos entities are formed by long fibrous crystals and are
classified into two groups: the amphiboles (amosite, crocidolite, anthophyl-
lite and actinolite) and the serpentine (chrysotile) group. The amphiboles
group of minerals are formed by double chain of SiO4, and in most cases also
contains iron and/or magnesium. The serpentine group are formed by ((Mg,
Fe)3Si2O5(OH)4) and can contain small amounts of other elements such as
chromium, cobalt, manganese or nickel. The chrysotile accounts for 95 % of
asbestos used [10].
Figure 1.3: Asbestos fibers taken with a scanning electron microscope. The
size of the breathable asbestos fibers are up to 20 µm [11].
The asbestos industry began in the mid 19th century when anthophyllite
was mined for use as asbestos insulation [12]. Later on, in the mid 20th
century, it was used in concrete, cement pipe, heat insulation, electric wire
insulation, clothes (fireproof coating), mastics, boilers and cigarette filters
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[13]. Asbestos was used mainly for its inexpensive cost and for its physical
properties such as fire resistance, good insulating qualities and flexibility.
The mining of asbestos in the United States increased over the 20th century
and reached a peak in the 1960s. At this time 136’000 tons were being
produced though this was ceased in the 1990s. However worldwide asbestos
production continues today with 2 million tons produced in 2012 and 200
million tons available world wide [14].
In 1960, Wagner et al. were the first to show a correlation between expo-
sure to asbestos and the development of pleural mesothelioma [2]. However,
it was only in the late 1980’s that western industrialized countries started to
ban asbestos (1989 in Switzerland, 1993 in Germany, 1997 in France). This
is still not the case for developing countries, such as China, India and Russia
where asbestos is commonly used.
Asbestos was a common construction material used in the last century. It
now requires specialized removal at great expense which is usually left until
a major renovation or demolition is performed. When buildings containing
asbestos are demolished, asbestos fibers can be released in the air. This
was the case when the Twin Towers collapsed in 2001 releasing 1000 - 2000
tons of asbestos in the air. The volunteers helping at ground zero as well as
the people caught in the cloud released by the collapse of the towers were
contaminated by asbestos and heavy metals. A survey of volunteers in 2008
reported respiratory problems in 62 % of people [15].
When asbestos is inhaled, most of the fibers are trapped in the lung
and the pleural region causing irritation and inflammation. The steps that
lead to mesothelioma are currently unclear. Nevertheless, current research
showed that many types of DNA-interacting proteins have an affinity for as-
bestos [16]. These interactions may cause disturbances in the cell division
and cause chromosomal aberration leading to mesothelioma. They suspect
that asbestos will act as a catalyst where oxidative modification will occur.
Proteins and DNA, inter alia, will be oxidatively modified by these mecha-
nisms [16]. These modifications are linked to carcingenesis.
1.4 Symptoms of malignant pleural
mesothelioma
The early symptoms of mesothelioma are similar to those of other illnesses
such as the common cold or pneumonia. Therefore, the correct diagnosis
of mesothelioma can be difficult and take weeks to months. A key element
in the diagnosis is the history of exposure to asbestos some 20 to 50 years
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prior to symptoms. Common symptoms include respiratory problems such
as a reduction of the respiratory function or shortness of breath, cough, pain
in the chest and fatigue can also be observed. For peritoneal mesothelioma
additional symptoms can be observed such as weight loss and abdominal
swelling. The radiological diagnosis of mesothelioma is generally performed
with computed tomography and/or with magnetic resonance imaging. A
biopsy sample establishes the definitive diagnosis.
1.5 Treatment modalities for malignant
pleural mesothelioma
Currently, there are several modalities available for the treatment of MPM
patients but so far no conclusive standard has been accepted. Single modal-
ity therapy and bimodality therapy has shown limited success with regard
to the local control [17, 18]. Surgery alone showed no improvement in re-
spect to survival [19]. When surgery and chemotherapy are used, a median
survival rate of 19 months (vs. 13 months no treatment) was reported [12].
In the early 1990s, a trimodal approach has been propagated. It consists of
chemotherapy, followed by surgery (extrapleural pneumonectomy or pleurec-
tomy/decortication) and radiotherapy. The first trimodality approach was
reported by Sugarbaker in 1991 [20]. In this study, the perioperative mortal-
ity rate was 6 % with a morbidity rate of 16 %. The survival rates were 70
% and 48 % after 1 and 2 years respectively.
1.5.1 Surgery
Currently, there are two different approaches used for MPM surgery: ex-
trapleural pneumonectomy (EPP) and pleurectomy/decortication (P/D). For
EPP, the surgeon removes the ipsilateral lung, diaphragm, pericardium and
the complete pleural envelope. For P/D, the outer pleura and the parietal
pleura are removed whilst sparing the lungs. During the 1970s, mortality
rates of up to 30 % were observed perisurgery [21]. With the improvement
of the surgical technique, patient selection and postoperative care, the mor-
tality rate was reduced to less than 3 % [22,23]. Nevertheless, postoperative
complication rates still remain high with an overall complication rate of 60
% and major complications reported in 22 % of operated patients [19]. Post
operation complications can include, inter alia, atrial fibrillation, prolonged
intubation, vocal cord paralysis [22]. The optimal surgical intervention is
controversial, mainly due to the small number of patients analyzed and the
patient selection criteria [24].
1.5. Treatment modalities for malignant pleural mesothelioma 13
1.5.2 Chemotherapy
Chemotherapy is the treatment of cancer with drugs that usually kill cancer
cells. It stops or slow down the growth of cells that divide rapidly. The
current drugs used for the treatment of MPM are cisplatin, carboplatin and
pemetrexed. In the case of mesothelioma, chemotherapy alone will not cure
the patient but can slow down progression and reduce the spreading of the
cancer. Chemotherapy alone has failed in respect to prolongation of survival
time [18].
When chemotherapy is combined with surgery, it can be given before
or after the surgery. The concept of preoperative chemotherapy has been
propagated by Stahel and Weder at the University Hospital Zurich and has
been widely accepted [23].
1.5.3 Radiotherapy
Radiation therapy has been used as a medical therapeutic modality since the
begining of the twentieth century, honored by a Nobel Prize to N.R. Finsen
in 1903, only height years years after the discovery of x-rays by W. Roentgen
in 1895 (Nobel Prize in 1901). Radiation therapy uses ionizing particles such
as photons, electrons, protons, neutrons or heavy charged particles. These
particles will interact with the cells leading to permanent damage of cellular
components such as proteins or DNA. These modification of the cells can lead
to there death. Ionizing radiation was first used clinically to treat skin disease
either with radioactive substances, such as radium, or with conventional x-
rays tubes. These x-rays tubes, which are still being used today for the
treatment of skin cancer, generates x-rays up to 300 kV (orthovoltage). The
advantage of these low energy x-rays is the maximal dose deposition which
is given to the surface. Furthermore, the dose fall-off is strong for these low
energies. Typically, for a beam having a half-value layer (HVL) of 0.1 mm
of aluminium, corresponding to an energy around 20 kV, the dose remaining
after 1 cm is below 10 % for an applicator having a source skin distance
of 30 cm and a 10 cm round applicator [25]. This value will increase with
larger HVL. For example, for a beam having a HVL of 1.0 mm of cupper,
corresponding to an energy around 200kV, the dose is 95 % at 1 cm, 60 %
at 5 cm and 30 % at 10 cm depth for a source skin distance of 50 cm and
a 10 cm round applicator [25]. The disadvantage of orthovoltage therapy is
that the beam does not penetrate deep enough to treat deep-seated tumors.
In the mid-1950’s, the first cobalt machine was used to treat deep-seated
tumors. The photon energies emitted from the disintegration of colbalt-60
was 1.17 MeV and 1.33 MeV. With these photons energy, skin sparing was
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possible. Beside the cobalt machine, linear accelerators were also used for
the treatment of deep-seated tumors. The principles of the linear accelerator
were developed by Cockcroft and Walton in the 1920s (Nobel prize in 1951),
and Luis W. Alvarez developed the first linear particle accelerator based in
Berkley in 1947(Nobel prize 1968). The first linear accelerator used for treat-
ing cancer patients was introduced in 1956 by H. Kaplan and E. Ginzton. In
the early 21st century, linear accelerators are the standard machines generat-
ing megavoltage beams for cancer treatment in the industrialized countries.
Linear accelerators have the advantage of generating beams with high en-
ergies, typically between 4 MV and 22 MV. This allows better sparing of
the skin and in the case of deep seated tumors better dose at depth when
compared to cobalt units.
Figure 1.4: TrueBeam linear accelerator from Varian (Varian Medical Sys-
tem, Palo Alto, USA). The patient is positioned on the couch which can
rotate around a fix point, called the isocenter, usually placed in the tumor
center. The gantry and collimator can both rotate around axes through the
isocenter. High energy photons from 4 MV to 22 MV as well as electrons
with energy ranging from 4 MeV to 22 MeV can be generated by the same
linac.
Linear accelerators, see Fig. 1.4, accelerate electrons to energies typically
between 4 MeV and 22 MeV in a dedicated shaped resonator. The acceler-
ating power is supplied by a microwave radio-frequency field. The electrons
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can directly be used for patient treatment. In order to treat large volumes,
the narrow electron pencil beam generated by the linac has to be broadened.
Most of the linear accelerators use two scattering foils for this purpose. The
first foil has a high atomic number and a homogeneous thickness in order
to scatter the electrons. The second foil, which can be approximated to a
cone shape, generates a homogenous energy fluence distribution. If photons
needs to be generated by the linear accelerator, the electrons are accelerated
and focused on a target with a high atomic-number, usually tungsten. The
energy lost by the electrons is converted into bremsstrahlung radiation. The
main direction of photons generated by bremsstrahlung with megavoltage
energy is in the motion direction of the electrons. Therefore, a cone shaped
attenuation filter (flattening filter) is placed in the beam in order to have
a homogeneous energy fluence distribution. The field is then collimated by
jaws and/or a multileaf collimator and blocks, see Fig. 1.5.
Figure 1.5: Diagram of an Elekta linac head showing the position of the
primary collimators, filters, ion chamber, wedges, leaves, and the secondary
collimators (X and Y back-up diaphragm) [26].
In radiotherapy, one of the goals is to achieve a sufficiently high minimal
dose in the clinical target volume (CTV) while keeping the dose to the organ
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at risks (OAR) as low as possible in order to avoid complication. In other
words, to deliver a dose high enough to achieve a high tumor control prob-
ability (TCP) and to achieve a low normal tissue complication probability
(NTCP), see Fig. 1.6. TCP and NTCP are both represented by sigmoid
curves. If the two curves are close to each other, a small increase in dose will
increase TCP and NTCP. If the TCP and NTCP are separated by a large gap
and the TCP is on the left side of the NTCP curve, an increase in dose will
increase the TCP without changing the NTCP. The gap between the TCP
and NTCP curves can be affected, inter alia, by changing the sensitivity of
the cells (drugs, oxygen) and by radiation and radiotherapy modalities such
as photons, neutrons or charged particles. Furthermore, the energy fluence
distribution of these particles can be modulated in order to improve the tar-
get dose coverage and dose conformity. By doing so, the TCP will increase
and the NTCP will decrease. In all of these treatment modalities previously
mentioned, a computed tomography (CT) based patient model and a linac
simulation is required in order to calculate the dose distribution computer
based individually which takes into account patient anatomy information.
Figure 1.6: Relationship between NTCP and TCP. The goal of radiotherapy
is to have a large therapeutic gap as possible. This gap will be influenced
inter alia by the radiotherapy modalities.
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3D-Conformal Radiotherapy and electron therapy
The 3D conformal radiotherapy (3DCRT) technique uses photons and more
rarely, electrons. Photons and electrons for treatment purposes are com-
monly generated by a linear accelerator producing photons with energies
ranging from 4 MV to 22 MV and electrons with energies ranging typically
from 4 MeV to 22 MeV. Depending on beam energy, maximal dose deposition
occurs at depths between 1 cm and 4 cm, see Fig. 1.7. The dose deposition
of the photons after the depth of maximal dose will decrease exponentially
due to absorption. Dose deposition is also dependent on the distance to the
source, r, and decreases with the relationship of 1/r2. Therefore, the dose
delivered distal from the target is not negligible, see Fig. 1.7. For electrons,
a stronger dose fall-off occurs after the depth of maximal dose than photons,
allowing better dose sparing of the tissue beyond the target. This fast dose
fall-off for electrons is an advantage when the target lies in close proximity
to the surface. When the target is beyond 6 cm, good coverage and dose
homogeneity is no longer achievable with electrons.
Figure 1.7: Percent depth dose curves for electrons, photons and protons.
Electrons and protons shows a faster dose fall-off compared to photons [27].
In order to have good dose conformity, the electron beams are collimated
18 1. Introduction
with blocks and the photon beams are collimated with a multileaf collimator
(MLC), see Fig. 1.8. The beams are collimated to the projection of the tumor
from the beam’s eye view direction. In order to increase conformity and have
a homogenous dose in the target, multiple beams from different directions
are commonly used.
Figure 1.8: Millenium microleaf collimator from Varian. The leaf width at
isocenter is 0.5 cm over the central 20 cm of the field and 1 cm on the edge of
the field over 20 cm. There is a motor for each of the 120 microleaves which
are able to move independently [28].
Electrons and photons fields are rarely combined in a plan due to the
difficulty and the time required to match electrons and photons fields. Low
dose electron isodose lines have a characteristic pear shape due to the scat-
tering of the electrons. For photons, the energy is deposited mainly in the
forward direction resulting in low energy deposition and sharp gradients later-
ally. Therefore, it is difficult to achieve good dose homogeneity and coverage
when combining electrons and photons fields.
Intensity modulated radiotherapy
In intensity modulated radiotherapy (IMRT), the energy fluence distribution
of the beam is modulated during treatment. This has the potential to create
steep dose gradients between PTVs and OARs and increase the gap between
NTCP and TCP curves. The fluence of the beam can be modulated using
various techniques. Physical compensators modulate the beam by absorption
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of the photons through compensators. This technique has important disad-
vantages, such as the time required for the fabrication of the compensators,
the need for the therapist to enter the room and change the compensator
after each field [29]. Two other techniques, step-and-shot and dynamic MLC
(dMLC) methods, use a conventional multileaf collimator (MLC) to modu-
late the intensity, see Fig. 1.8. For the step-and-shoot method, the fluency is
divided into multiple segments. In each segment, different MLC positions are
defined. The beam is turned on when the MLC’s are at the right position,
and turned off between segments in order to allow the MLCs to move from
one predefined position to the next, see Fig. 1.9. Drawbacks of this technique
are, inter alia, long delivery time and the necessity of a good linearity of the
linac output and profiles for segments treated with few monitor units.
Figure 1.9: Field segments for a ”step and shoot” IMRT technique (first
5 images) and the resulting dose-map fluence (last image). The dose-map
fluence is in arbitrary units and the scale range from dark blue to pink (scale
is displayed on the left side of the last image).
In the dMLC-sliding window method, the intensity is modulated by the
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leaves which are independently moving at different velocity when the beam is
on. The gap between two opposing leaves also varies during the irradiation.
This gives a short delivery time, but requires a very precise MLC controller
to verify the leaf positions. This is required in order to have a delivered dose
distribution as close as possible to the calculated dose.
Figure 1.10: Example of dose volume constraints for organ at risks set during
the inverse planning process. The planner set constraints (triangles) and the
algorithm tries to fulfill the objectives. In the current example, the two
constraints on the right side are achieved (the curve is on the left side of the
constraints) and the three constraints on the left side are not fulfilled since
the dose to the structure is higher than what is planned.
IMRT treatment plans are generated with a treatment planning system
using in general inverse planning. For inverse planning, dose volume con-
straints are set by the planner based on clinical information. For example,
target and organ at risk will have upper constraints such as ”not more than x
% of the volume should receive more than y Gy”, see Fig. 1.10. For targets,
additional lower constraints will be set such as ” x % of the volume or more
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should receive at least y Gy”. These constraints are set during the optimiza-
tion process and will be taken in an objective function. This function will be
optimized in order to get as close as possible, or to achieve, all the constraints
previously defined [30]. Therefore, the weight of each beamlet for every field
will be optimized resulting in a fluence distribution generated by different
MLC positions during the irradiation (for step-and-shoot and sliding win-
dow techniques). Today, most of the objective functions are based on dose
parameters and becoming more common based on radiobiological models.
Different types of algorithms are used in the optimization and calculation
process. Most of them use a fast simplified algorithm in the optimization
of the objective function. This allows to optimize the plan in a reasonable
time, i.e. in a couple of minutes. Therefore, for the optimization step, the
pencil beam algorithm [31] may be preferred to Monte Carlo [32] due to their
faster calculation time. For the dose calculation on the planning CT, more
robust algorithms are preferred, such as Monte Carlo, Acuros (based on the
linear Boltzmann transport equation), or collapse cone convolution. These
algorithms are more suitable to take into account density inhomogeneity and
display a dose distribution closer to the dose delivered when compared to
simpler algorithms such as pencil beam.
Volumetric modulated arc therapy
Volumetric modulated arc therapy (VMAT), also called intensity modulated
arc therapy (IMAT) or RapidArc R© (Varian Medical Systems, Palo Alto,
CA, USA), is a kind of rotational IMRT where gantry angle, dose rate and
MLC positions are changing during the irradiation. At each gantry angle
position of an arc, a single aperture shape is formed by the MLC. No motion
of the leaves is performed at a fixed gantry angle as it is the case for IMRT.
During the rotation of the gantry, the speed of the gantry as well as the dose
rate are modulated. This allows each leaf of the MLC to reach its position
for each control point. This technique can be delivered with a C-arm shaped
linac.
Some planning systems are using a direct aperture optimization (DAO) in
their algorithms [33]. The aperture is optimized for each control point which
corresponds to a gantry angle using an annealing algorithm. At the beginning
of the optimization (for RapidArc R©), a small number of equidistant control
points are used, typically five. The number of control points increases during
the optimization process to reach a number of 177 control points for a full
arc rotation for RapidArc R©. The initial aperture shape for a new control
points is interpolated between adjacent control points.
During the optimization process, random modifications of the fluence are
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applied and are accepted when an improvement of the objective function
is observed. These modifications have to fulfill the linac limitations such as
gantry rotation speed, MLC speed and dose rate. The optimization normally
stops after a given time or a given number of iterations. The algorithms used
for the dose calculations are similar to those used for IMRT.
Proton therapy
Proton therapy (PT) as 3DCRT, IMRT or VMAT is an external beam radio-
therapy technique which uses protons instead of photons for the treatment
of cancer. The advantage of PT comes from the interaction of protons with
tissue, see Fig. 1.7. There is less lateral scatter than for photons and elec-
trons. More important is that most of the energy deposition occurs in the
last few millimeters where the protons are completely stopped. The maxi-
mal dose peak is called ”Bragg peak”. The depth of the Bragg peak depends
on the proton energy. This is a big advantage in comparison to photons
where megavoltage photons delivers the maximal dose between 1 cm and 4
cm depth and the beam delivers dose beyond the target which is not the case
for protons. In order to cover larger volumes with good dose homogeneity
with PT, different energies are combined in order to move the Bragg peak
forward or backward. This results in a plateau, called the Spread-Out Bragg
Peak (SOBP), as shown on Fig. 1.13. After the SOBP, nearly no dose is
deposit, allowing the treatment of targets which are in very close proximity
to critical structures. There are currently two different approaches for PT
dose delivery:
Figure 1.11: Principle of the passive spreading technique. The proton energy
is modified by filters. The proton beam is then broaden by two scatterers
and then collimated by a collimator and a compensator [34].
• Passive spreading also called scattering method. In this approach, the
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proton beam is broadened by placing material in the beam. A single or
a double scattering foil are used depending on the field size. In order to
confrom the dose to the target a patient specific compensator is used,
see Fig. 1.11
• Active spreading, also called spot scanning. The protons are focused
by electric and magnetic fields at a given location within the tumor. By
using multiple spots, it is possible to scan the dose through the entire
target, treating voxel-by-voxel, see Fig. 1.12.
Figure 1.12: Dose distribution for a single pencil beam (first picture) to
thousand pencil beams superimposed (last picture) [35].
PT can be used in similar way as the 3DCRT by using fields coming from
different directions, all of them delivering a homogenous dose in the target.
The IMRT approach can also be used with protons, this technique is
called intensity modulated proton therapy (IMPT). With IMPT the fluency
is modulated for each spot but the combination of all the fields leads to a
homogenous dose in the target and a very good sparing of the healthy tis-
sues can be achieved. In theory, there is a clear advantage of protons over
photons and electrons therapy due to the depth dose characteristics. On
the other side, protons will be much more affected by patient miss-alignment
and changes in the patient anatomy. This could lead to a target underdosage
and/or an organ overdosage. An other disadvantage is the neutron contam-
ination due to the proton-nuclear interaction. This neutron contamination
could result in an increase of developing secondary cancer [36].
1.5.4 Photon treatment planning algorithms
Before the energy of the photons generated by a treatment machine is ab-
sorbed by the patient, a lot of interactions occur. The dose deposited at a
given point in the patient can be divided in four main components [37]:
• Primary fluence. This results in around 70 % or more of the total
deposited dose and is created by photons generated in the target.
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Figure 1.13: Proton dose deposition for different energies (green curves). The
total dose deposited by all the proton beams are displayed in black showing
a plateau in the target region (blue shaded region). After the target, a steep
dose fall-off is observed with minimal dose delivered to the tissue after the
target.
• Phantom scatter. This can produce up to 30 % of the total deposited
dose. Scattered photons are generated by the interaction of the primary
photons in a body.
• Head scatter. This typically contributes to 5 % to 10 % of the total
dose. This energy is transported by photons originating in the head
of the treatment machine excluding the target. These photons can
be generated in the flattening filter, in the collimator system (jaws or
micro-leaf collimator) or in the air column after the target.
• Contaminating charged particles present in the photon beam. There
are generated in the flattening filter in photon beams. The dose depo-
sition of these charged particles will take place in the first centimeters
of the absorbing body. The depth depends on the energy of the beam.
All of these interactions which occur in the machine as well as in the pa-
tient are schematized in Fig. 1.14. These interactions are taken into account,
implicitly or explicitly, depending on the sophistication of the algorithm used
for dose calculation in the planning system. The dose calculations methods
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are often divided into two groups. The empirical method also called broad-
beam where no distinction between the type of interactions are considered.
The superposition method on the other hand, takes into account all the dif-
ferent types of interactions.
Figure 1.14: Main interactions and dose deposition of megavoltage photon
beams in patients [37].
Empirical Methods
In the empirical methods two approaches can be used to calculate the dose
distribution:
• Measured data under reference condition are used for the dose calcula-
tion. These data are stored in a table and are interpolated during the
calculation process.
• Based on measured data, mathematical functions are used to fit profiles
and depth-dose curves. Based on these functions a dose distribution at
non reference conditions can be calculated
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Correction factors are used in empirical methods to take into account
differences between reference conditions and treatment conditions. For ex-
ample corrections for the variation of the source skin distance, patient inho-
mogeneities. If a high accuracy in dose calculation is required and complex
beam arrangements are used, for example in intensity modulated radiother-
apy, empirical methods reach their limits. More powerful algorithms based
on the superposition principle, for example, are then preferred.
Superposition methods
In the superposition methods, the dose is calculated voxel by voxel. The
dose, DP , deposited at any point P (x, y, z) can be considered as a sum of
contribution of dose coming from each point P (x’, y’, z’), see Fig. 1.15. The
main disadvantage of this approach is the large amount of computer time
required to calculate the dose distribution.
Figure 1.15: The dose at point P can be considered as the dose coming from
the interaction of the primary photons interacting in the volume dV [26].
1.5. Treatment modalities for malignant pleural mesothelioma 27
1.5.5 Planning evaluation
In the planning process, especially during inverse planning, there are con-
tradictory objectives. These include high and uniform dose to the target
on one side and low dose to the surrounding healthy tissues on the other.
Furthermore, different objectives can be set for the target and the organ at
risk. Therefore, there is not a unique ”best plan” achievable. If a plan can
be optimal for a given structure without deteriorating the other structure,
such solution is called a Pareto optimal solution. This can be repeated for
each structure leading to a set of solutions constituting the Pareto front [38].
In the current planning evaluation process, the Pareto front is not avail-
able, only a subset of optimal plans can be generated by the planner. There-
fore, plan comparison tools are required in order to compare different plans.
This can be performed by comparing the dose distribution slice by slice.
This process is time consuming, and most of the time no clear answer can
be given. In most cases a plan determined to be better at sparing some
organs and/or delivering a better dose coverage to part of the PTVs. In
combination with the isodose representation of the dose distribution, dose
volume histogram (DVH) parameters are often used to describe plan quality.
These DVH parameters reduce the DVH curve to a single or multiple quan-
titative parameter. These parameters include the mean dose, maximal dose
or minimal dose to 95 % of a certain volume. This allows the comparison
of 2 different plans as well as parameters able to be compared to published
data. The disadvantage of this techniques comes from the loss of information
when the graph is reduced to a small number of values. Thus to take into
account all available parameters of the DVH and the specificity of the or-
gans or the target structure, the equivalent uniform dose (EUD) can be used.
The definition of the EUD given by Niemierko was: ”The concept of equiv-
alent uniform dose assumes that any two dose distributions are equivalent if
they cause the same radiobiological effect” [39]. He suggested the following
formula for target volumes and organs at risk:
EUD =
(
1
N
N∑
i=1
Dai
) 1
a
(1.1)
Where N is the number of voxels in the structure of interest, D is the dose
in the voxel i, and a is the tumor or organ parameters that describes the
dose-volume effect [40]. These parameters can be calculated from published
normal tissue tolerance dose [41,42]. When a = -∞ the EUD is equal to the
minimal dose in the structure of interest. When a increases to +∞, the EUD
will tend to the maximal dose in the structure of interest. In the upper graph
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from Fig. 1.16, a typical lung dose volume histogram is displayed. The EUD
for the lung dose volume histogram is displayed as a function of parameter a
in the lower graph from Fig. 1.16. The EUD concept can be used either for
target structures or for organs. The value for a is typically between 1 and 10
for organs. For targets, negative values for a are taken in order to take into
account cold spots in the target and positive values are also taken in order
evaluate hot spots in the target.
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Figure 1.16: The upper picture represents a typical lung dose volume his-
togram for a mesothelioma patient planned with IMRT. The lower picture
gives the EUD as a function of the parameter a, ranging from -15 to 15 for
the graph above.
Knowing the biological equivalent dose that, if given uniformly, would
lead to the same radiobiological effect, tumor control probability as well as
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normal tissue complication probability can be derived from the EUD value
[40,43].
1.5.6 Adaptive radiotherapy
In radiotherapy the treatment delivery accuracy has a direct impact on the
target margins [44] 1. Furthermore, poor patient positioning could lead to
target underdosage and/or overdosage of the organs at risks. Therefore treat-
ment delivery accuracy is integral in maintaining the planned tumour control
probability and normal tissue complication values. Patient positioning can
be performed based on integrated imaging modalities such as cone beam
computed tomography, kV of MV images. These images are then registered
to the planning CT. This process can be difficult when anatomical changes
occur in the patient, for example tumor shrinkage or tumor motion. This also
occurs during the treatment of mesothelioma patients where change of den-
sity in the resected lung is observed after surgery [B]. Indeed, after surgery,
air and/or fluid will take the place of the resected lung. The air cavity will
disappear with time and will be subsequently replaced by fibrous tissue or
fluid, see Fig. 1.17.
The change in the air cavity volumes can be seen on a lateral MV or kV
image or more easily with a cone beam CT or conventional CT. The vari-
ation in the air cavity volume in the resected lung changes the CT density
from 0 to 1 and will affect the patient external anatomy. This will change
the density distribution and the radiographical path lengths in the resected
lung. These changes will affect the absorption of the photons and particles
used during radiotherapy leading to a change in the dose distribution [B].
Therefore adaptive radiotherapy is required in order to modify the original
plan to take into account changes in patient anatomy. Adaptive radiotherapy
is the adaptation of the treatment plan on changes in the patient geometry,
anatomy and morphology during the radiotherapy treatment in order to im-
prove radiation treatment success [46]. These modifications are performed
in order to take into account in changes in patient anatomy, modification of
the tumor size or change in tumor location. Therefore, on-line and off-line
approaches can be used in order to assess these changes. With the on-line ap-
proach, an adaptive plan is performed based on a cone beam CT taken prior
to radiotherapy treatment. This approach is currently used only for small
tumors such as those in the prostate [47] due to technical issues (maximum
size of the cone beam CT in the cranial-caudal direction is currently limited
1 A margin around the tumor is applied to take into account the accuracy of the delivery
among other things. The volume treated will be the tumor and the margin volume in
order to ensure that the wished dose is delivered in the tumor.
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a) b) c)
Figure 1.17: Variation of air cavities during radiotherapy treatment. These
three images have been taken with a kV imager from 90 degrees. The left
image has been taken on the first day of radiotherapy treatment. Image b was
taken at fraction 12, 16 days after the first radiotherapy treatment. Image c
was acquired on the last day of treatment, 31 days after the first radiotherapy
treatment. The purple structure in the middle of the picture represents the
vertebra column. The black structure on the chest wall represents the air
cavity.
to 20 cm) and the time required for reoptimization which is correlated to the
target size. For large tumors, such as mesothelioma, the off-line approach is
the only one currently available for adaptive radiotherapy. In this approach,
conventional CT will be required due to the dimension of the tumor, up to
40 cm in the cranial-caudal direction.
Image registration
In adaptive radiotherapy, planning CT and online acquired cone beam CT are
registered in order to verify the patient positioning as well as a modification
in patient anatomy before starting the treatment. After the registration
process, volume propagation can be performed from one set of images to
the other set. Several publications have presented different approaches for
registration. Here, only a short summary will be presented [48,49]. Following
the classification formulated by Elsen et al. [50], registration algorithms can
be either extrinsic or intrinsic. In the extrinsic registration, the patient
datasets are matched based on artificial markers. These markers can be non-
invasive such as skin markers, or invasive, such as a stereotactic frame screwed
into the patients skull. The extrinsic registration is a fast and easy method.
This approach is mostly used for rigid registration such as cranial stereotaxy.
The non-rigid registration approach often fails due to the lack of deformation
1.5. Treatment modalities for malignant pleural mesothelioma 31
information coming from the markers. Indeed, a very high number of markers
would be needed in order to obtain enough information on the deformation.
The intrinsic registration uses the patient’s image structures such as the body
contour, anatomy landmarks, pixel intensities and bone structures.
There are three main types of intrinsic registration. They can be based
on:
• Landmarks. Registration with landmarks can be separated in two
groups: anatomical or geometrical. The anatomical landmarks are
based on locatable anatomical structures. The geometric landmarks
are points derived from various shapes such as curvatures minima or
extrema. This registration is often used for rigid registration due to
the lack of deformation information.
• Segmentation. In the segmentation registration, anatomic structures,
in most cases, surfaces, are taken from both data sets for registra-
tion. This registration can either use a rigid registration or deformable
model. This approach is often used for head registration which relies
on the skin surface from the different image modalities [49]. This allows
an easy and quick registration.
• Voxel properties. In this registration method, the grey value of the
images are taken in order to register two sets of images. In this ap-
proach, no data reduction is requested as it the case for the segmenta-
tion registration. This kind of registration can either be used for rigid
or deformable models. The main drawback of this registration is the
high computer power/memory required [49].
For all these types of registration, the nature of the transformation can
differ, be it rigid, affine, projective or curved. In rigid transformation the
two image sets will be moved in order the keep the objects as close to each
other while keeping the shape and geometrical correlation of the objects un-
changed. Therefore, only translations and rotations are allowed. In the affine
registration, the objects are segmented and a straight line in the first image is
mapped onto a straight line in the second image [50]. The parallelism is pre-
served in this method. A projective transformation is an affine registration
where the parallelism is not preserved. In other words, the transformation
maps lines to lines. In the curved registration, also called elastic registration,
the object is segmented and a straight line in the first image is mapped onto
curved lines in the second image, see Fig. 1.18.
Transformations are called global when the transformation is applied to
an entire data set and local if each subsection of the data set has its own
transformation, see Fig. 1.18.
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Figure 1.18: Example of different types of registration [49]. In the rigid
registration, only translation and rotation transformation are allowed. For
the affine registration, objects are segmented and straight lines are mapped to
straight lines. For the elastic registration, straight lines are mapped to curved
lines. The registration is called global when the transformation is applied to
the entire data set and local if each subsection has his own transformation.
1.6 Aims of this study
Currently there are no standard procedures for the treatment of MPM pa-
tients. Different studies are currently running to show what are the benefits
from the different modality combinations. For example we are investigating
the benefit of radiotherapy in the tri-modality approach [51] 2, in the Swiss
group of clinical cancer research (SAKK)3. Nevetherless, there is not yet a
general agreement on which treatment modality should be used. The goal
from this PhD thesis was to compare different external beam radiotherapy
treatment techniques, such as 3DCRT, IMRT, VMAT and PT, for the treat-
ment of MPM patients after EPP. This was performed based on clinical data,
2 Tri-modality treatment is the combination of neoadjuvant chemotherapy surgery and
radiotherapy.
3 J. Krayenbuehl is the responsible medical physicist for this national study
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planning comparison and plan robustness. A non-rigid algorithm was also
developed for the purpose of adaptive radiotherapy.
In more details, chapter 2 and chapter 5 gives an evaluation of the possi-
bility to treat MPM patient with IMRT. Evaluations of patient clinical data
such as local control, disease free survival, overall survival have been done
for 3DCRT and IMRT in chapter 5. Furthermore, an evaluation of optimal
3DCRT and IMRT plans has been performed in chapter 2. The dosimetric
advantages of both techniques were assessed based mainly on dose volume
histogram parameters.
A feasibility study on the use of proton therapy (PT) and volumetric
modulated arc therapy (VMAT) has also been performed. The results are
presented in chapter3, 4 and 5. These two techniques were compared to
IMRT in respect to dose distribution and treatment time. Also for con-
sideration is the instability of tissue density in the ipsilateral hemithorax
following an EPP procedure. The EPP will leave variable air cavities which
are subsequently replaced by fibrous tissue, see chapter 3 and 4. These air
cavities variations will affect the anatomy and the density of the ipsilateral
lung resulting in a modification of the dose distribution. The dynamic of
volume decrease has been evaluated and the results are presented in chapter
3 and 4. The modification of the dose distribution due to the modification of
patient anatomy was performed for the targets and the organs at risk. This
evaluation has been done based on the equivalent uniform dose (chapter 3)
and dose volume parameters (chapter 4) for IMRT, VMAT and PT.
In order to take into account the deformation of the patient anatomy
during the treatment, adaptive radiotherapy can be used. Images have to be
registered in order to propagate volumes from one set of images to another
set of images. This volume propagation was evaluated using a new approach
using non-rigid registration. In order to validate this algorithm, a comparison
between automatic segmentation (affine and non-rigid registration) and man-
ual segmentation was performed. This validation was performed on prostate
cancer patients due technical reasons (size of the target, computation time
and accessibility to control CTs). The results from this study are presented
in chapter 6.
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2 1. 3DCRT vs. IMRT for MPM after EPP
1.1 Abstract
The optimal technique for postoperative radiotherapy (RT) after extrapleu-
ral pleuropneumonectomy (EPP) of malignant pleural mesothelioma (MPM)
remains debated.
The data from 8 right-sided and 9 left-sided consecutive cases of MPM
treated with RT after radical EPP were reviewed. Of the 17 patients, 8
had been treated with three-dimensional (3D) conformal RT (3D-CRT) and
9 with intensity-modulated RT (IMRT) with 6-MV photons. The clinical
outcome and adverse events were assessed. For comparative planning, each
case was replanned with 3D-CRT using photons and electrons or with IMRT.
Homogeneity, doses to the organs at risk, and target volume coverage were
analyzed.
Both techniques yielded accepteble plans. The dose coverage and homo-
geneity of IMRT increased by 7.7 % for the first planning target volume and
9.7 % for the second planning target volume, ensuring ≥ 95 % of the pre-
scribed dose compared with 3D-CRT (p < 0.01). Compared with 3D-CRT,
IMRT increased the dose to the contralateral lung, with an increase in the
mean lung dose of 7.8 Gy and an increase in the volume receiving 13 Gy
and 20 Gy by 20.5 % and 7.2 %, respectively (p < 0.01). A negligible dose
increase to the contralateral kidney and liver was observed. No differences
were seen for the spinal cord and ipsilateral kidney. Two adverse events of
clinical relevant lung toxicity were observed with IMRT.
Intensity-modulated RT and 3D-CRT are both suitable for adjuvant RT.
IMRT improves the planning target volume coverage but delivered greater
doses to the organs at risk. Rigid dose constraints for the lung should be
respected.
1.2 Introduction
The role of radiotherapy (RT) for palliative treatment of malignant pleural
mesothelioma (MPM) is well established [1, 2]. RT is effective for pain con-
trol in the case of thoracic wall invasion and is used for the prevention of
malignant seeding after invasive procedures [3,4]. The role of RT within the
setting of radical multimodal therapy is less well defined, although the tho-
racic relapse rates after extrapleural pleuropneumonectomy (EPP) of MPM
are high and adjuvant treatment is warranted. In recent years, adjuvant RT
has been advocated as a part of postoperative therapy, and various tech-
niques with different field geometries and dose schedules have been used
[5, 6]. More recently, neoadjuvant therapy with preoperative chemotherapy
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has been added to the treatment concept and has shown promising results
in specialized institutions [7].
The best-documented multimodal potentially curative approach to MPM
is pleuropneumonectomy, combined with chemotherapy and RT (trimodality
approach) in selected patients with early disease stages. The survival rate of
a large series of 176 patients after surgery was 38 % at 2 years and 15 % at
5 years, with a median survival of 19 months [5]. More recently, preopera-
tive chemotherapy followed by EPP has been investigated, and its feasibility
has been reported in a multicenter trial [7, 8]. The benefit of preopera-
tive chemotherapy, however, will remain difficult to prove unless randomized
trials are initiated. In some cases, operable disease might progress during
chemotherapy, rendering subsequent resection more difficult. In our expe-
rience, the overall treatment time resulting from combined chemotherapy
followed by surgery and the protracted therapy-associated stress on patients
have made postoperative RT potentially more difficult and more challeng-
ing [9]. The radiation oncologist has to decide whether full coverage of the
hemithorax can be proposed or a treatment volume limited to the initial
tumor region is sufficient and feasible after chemotherapy and EPP in each
case. There is little doubt that preoperative chemotherapy can jeopardize
the benefits from RT because of cumulative toxicity and treatment-related
asthenia. Furthermore, no standard for either chemotherapy or RT exists. In
particular, the acceptable size of the target volumes, dose constraints, and
radiation techniques should be considered before implementation of RT in
multimodal settings.
We evaluated two RT techniques that were used in our center for the
purpose of RT after chemotherapy and surgery for MPM: three-dimensional
(3D) conformal RT (3D-CRT), used until 2004, and intensity-modulated RT
(IMRT). With both planning techniques, the entire ipsilateral hemithorax
was defined as the clinical target volume (CTV2), with a high-risk area rep-
resented by the macroscopically resected tumor (CTV1).
1.3 Methods and materials
For this retrospective treatment planning study, we reviewed the clinical
records of all patients (n = 17) diagnosed with MPM between 2000 and 2006
who were treated with chemotherapy followed by EPP and RT. All patients
had presented with Stage cT1-T3 N0-N1 M0. Mediastinal staging was done
using computed tomography (CT) and positron emission tomography/CT.
Mediastinoscopy was performed in all patients to exclude mediastinal in-
volvement; patients with mediastinal involvement did not qualify for EPP.
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The performance status before RT was Eastern Cooperative Oncology Group
score of ≤ 2 in all patients. Lung function before RT was assessed, and the
requirements for RT was a forced expiratory volume in 1 s of >1 L. In brief,
chemotherapy consisted of three cycles of pemetrexed 500 mg/m2 and cis-
platin 75 mg/m2, repeated after 21 days for a total of three cycles. Surgery
was done as described previously [7]. In brief, EPP yielded complete resec-
tion of all macroscopic tumor, and resection of invaded areas with suspected
microscopic spread of the thoracic wall, diaphragm, or pericardium was ac-
complished in each case. Reconstruction of the diaphragm was done in 11
patients. Of the 17 patients, 8 were treated with a conventional photon
technique (mean dose 53 Gy) and 9 with IMRT (mean dose, 55.9 Gy). All
cases were retrospectively replanned with IMRT or the conventional electron-
photon technique to compare the two techniques [10,11]. The patient group
consisted of 2 women and 15 men. At diagnosis, the median age was 60 years
(range, 46 - 66 years).
The patients were immobilized in the supine position using a body cast
and wing board, with their arms extended above their heads to grab a T-bar.
The planning CT scan was based on 3-mm CT slices with no gap. Two CTVs
were defined, from which the planning target volumes (PTVs) were derived.
CTV2 was defined as the field of surgery, including the entire preoperative
pleural and pulmonary structures and the surgical scars. CTV1 was defined
as the area at risk of residual postoperative microscopic disease or the area
of greatest risk of intrathoracic relapse, as determined by the surgeon. Af-
ter complete resection (R0 or R1), no macroscopic tumor was visible on the
postoperative radiographs. Thus, no gross tumor volume was available. The
CTVs were defined by the risk of relapse. CTV2 covered low-risk areas (< 50
Gy), and CTV1 covered high-risk areas, resulting in high-dose areas (> 50
Gy). A working CTV2 (wCTV2) was established first. The wCTV2 covered
the inner border of the thoracic cavity, the diaphragm, and the mediastinum
and surgical channels and was outlined using computerassisted 3D contour-
ing. With respect to the mediastinum, the ipsilateral hilar, subcarinal, lower
and upper ipsilateral paratracheal, and prevascular and retrotracheal lymph
nodes were included in the wCTV2. The para-aortic and subaortic lymph
nodes were included for left-sided disease or if nodal involvement had been
documented in right-sided disease. The paraesophageal lymph nodes and
lymph nodes of the pulmonary ligament were not included in the wCTV2,
unless microscopic contamination was suspected. The wCTV2 was expanded
to the final CTV2 with a margin of 0.4 - 0.5 cm. CTV1 was defined by the
areas of macroscopic tumor and, after detailed review of the CT scans with
the surgeon, included the areas of increased risk of relapse and macroscopic
disease, which might have been perceived differently during surgery than on
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the preoperative CT scans. The CTVs were expanded to the PTV, respecting
internal target movement variability and setup variability. The PTVs were
used for RT planning. The PTV2 margins were 1.2 - 1.5 cm in the caudal
direction, 1.0 cm in the cranial direction, 0.6 cm in the dorsal direction, 1.2
cm in the anterior direction, and 0.8 cm in the lateral direction. The PTV1
margins respected the localization of the CTV1. If the CTV1 was located in
the upper one-half of the hemithorax, breathing movements were assumed to
be less prominent than for CTV2s located in the lower hemithorax or adja-
cent to the diaphragm. The PTV margins for CTV1 in the upper hemithorax
were 1.0 - 1.2 cm in the caudal direction, 0.8 - 1.0 cm in the cranial direction,
0.6 cm in the dorsal direction, 1.0 cm in the anterior direction, and 0.7 - 0.8
cm in the lateral direction. If the CTV1 was located in the lower hemithorax,
the PTV margins were 1.2 cm in the caudal direction, 1.0 cm in the cranial
direction, 0.6 cm in the dorsal direction, 1 cm in the anterior direction, and
0.8 cm in both lateral directions. An example of a series of three coronal
views of a representative case is shown in Fig. 1.1.
1.3.1 Three-dimensional CRT
The treatment plan of the 3D-CRT patients included 25 x 1.8 Gy to the PTV1
and PTV2 followed by 7 x 1.8 Gy only to the PTV1. The ipsilateral kidney
(or liver, respectively) was shielded during the entire treatment from the
posteroanterior (anteroposterior and posteroanterior, respectively) direction.
The heart was shielded with a block after 19.8 Gy. When any point of the
spinal cord reached a dose of 45 Gy, the spinal cord was shielded. The target
volumes shielded because of dose limitations to the organs at risk (OARs),
regions under the ipsilateral kidney (or the liver in the case of right-sided
disease), retrocardiac space, and spinal cord were treated with electrons as
described previously by Kutcher et al. [12]. To compensate for the blocked
areas, electron fields were used. The electron energy range was 9 - 16 MeV,
and the photon energy was 6 or 18 MV. The electron fields accounted for
block transmission. The gantry angle used for the electrons and photons fields
was 0˚ and 180˚ , respectively. With this beam configuration, we obtained
the best compromise between target coverage and myelin avoidance. In 2
patients with left-sided disease, the PTV1 was dorsally and laterally located,
and customized gantry angles were used for the last seven fractions (from 45
Gy to 57.6 Gy). The photon beams angles used in these 2 cases were 190˚ and
45˚ for the first case and 200˚ and 40˚ for the second case. No electron fields
were used in these 2 cases, because the OARs were out of the fields. The dose
calculation for electrons and photons was performed on Pinnacle (Philips
Medical Systems) for a linear accelerator (Clinac 2100C, Varian Medical
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Systems, 80 multileaf collimator). The 3D-CRT plans were not delivered as
calculated in the present study. All patients were treated without electron
fields, and the corresponding clinical results have been previously reported
[7].
1.3.2 Intensity-modulated RT
Five radiation beams were used in the optimized IMRT plans for each patient.
The beam angles were patient-specific and ranged from 170˚ to 30˚ for left-
sided tumors and 330˚ and 200˚ for right-sided tumors. The angles between
two consecutive beams ranged from 45˚ to 70˚ . An example of a gantry set
used for a right-sided tumor was 170˚ , 220˚ , 280˚ , 330˚ , and 20˚ , and for a
left-sided tumor was 345˚ , 30˚ , 80˚ , 140˚ , and 195˚ . The gantry angles used
for the left sided tumor were used for the treatment of the targets displayed
in Fig. 1.1. The red structure represents the PTV1 and the green structure
the PTV2. The treatment of the IMRT patients was planned using 26 x 1.75
Gy (45.5 Gy) to the PTV2, including a simultaneously integrated boost of
26 x 2.15 Gy (55.9 Gy) to the PTV1.
Figure 1.1: Target volume definition. Areas of previous macroscopic tumor
involvement and areas causing surgical difficulties during radical resection
were treated with additional integrated or sequential boost, planning target
volume 1 (PTV1) (red). PTV2 (green) represents areas of previous pleural
extension.
Dose calculation and optimization were done using an inverse treatment
planning system, (HELIOS, Eclipse, version 7.3.2, Varian Medical Systems).
Treatment was delivered using a 6-MV linear accelerator (Clinac 6EX, Varian
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Medical Systems, 120 leaf Millennium multileaf collimator) using the sliding-
window technique.
Before the first session, quality assurance is routinely done. Quality
assurance is done using three different modalities: (1) film dosimetry, (2)
ionization chamber measurements; and (3) software verification. For film
dosimetry, the film (Kodak EDR2 Film, Eastman Kodak, Rochester, NY)
was placed horizontally at the isocenter under 5 cm equivalent water. The
gantry angle was set to 0˚ . A γ evaluation was performed for each single
field with an acceptance level of 5 % and 3 mm with our treatment planning
system. For the ionization chamber measurements, a PTW Farmer cham-
ber, 0.6 cm3 was used, and the measurements were done at the isocenter in
a cylindrical water equivalent phantom. A deviation of less than 5 % per
beam with our treatment planning system was accepted. Finally, the dose at
the isocenter was verified with an independent software program (RadCalc,
LifeLine Software, Tyler, TX) for each field. A deviation of less than 5 % per
beam with our treatment planning system was accepted. An overall error of
dose delivery inaccuracy of less than 3 % was requested. All plans had to
fulfill these criteria before the first treatment session.
1.3.3 Dose-volume constraints
The dose - volume constraints are listed in Table 1.1. The dose constraints
applied were calculated to 2 Gy/d equivalent dose, respecting an αβ ratio of 3.
The maximal dose to any part of the spinal canal was kept at < 50 Gy. The
mean dose given to the heart was limited to < 40 Gy, and the maximal heart
volume receiving 45 Gy was kept to < 30 %. The maximal mean lung dose
allowed was 15 Gy, and not >10 % of the lung volume could receive > 20 Gy.
The mean dose to the liver was not allowed to be > 3 0 Gy. The maximal
mean dose to the kidneys allowed was 12 Gy, and the volume receiving > 15
Gy was kept at < 20 %.
1.3.4 Plan comparision
For the comparison of the treatment plans, the dose - volume histograms
(DVHs) were normalized, so that the mean dose of PTV1 was equal to 55.9
Gy (2.15 Gy for 26 fractions). IMRT and 3D-CRT were compared using
DVH parameters after normalization for a single dose prescription.
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Normal tissue Constraints
Spinal cord
Maximal dose (Gy) < 50
Liver
Mean dose (Gy) < 30
Kidney
Mean dose (Gy) < 12
V15 (%) < 20
Lung
Mean dose (Gy) < 15
V20 (%) < 10
Heart
Mean dose (Gy) < 40
V45 (%) < 30
Table 1.1: IMRT optimization parameters. Abbreviations: IMRT =
intensity-modulated radiotherapy; V15, V20, V45 = volume of organ receiving
dose of ≥15, ≥20, ≥45 Gy, respectively.
1.3.5 Statistical analysis
Statistical analysis was performed using a paired t-test. The t-test and p
value were calculated with the software StatView (version 5.0.1) (SPSS Inc.,
Chicago, IL). A p - value of < 0.05 was accepted as significant.
1.4 Results
The percentage of the PTVs receiving < 95 % and the percentage receiving
> 105 % of the prescribed dose were assessed for 3D-CRT and IMRT. The
mean dose for all structures was assessed. The percentage of the kidney (or
heart) receiving > 15 Gy (or 45 Gy), the percentage of the lung receiving
> 13 and 20 Gy, and the maximal dose to the spinal cord were evaluated
Table 1.2. The reported values were averaged for the 17 MPM patients from
the present study. Dose delivery to the PTV was improved using IMRT.
Dose homogeneity was also improved with IMRT. The volume covered by
the 95 % isodose was increased by 7.7 % for PTV1 (p = 0.01) and by 9.7 %
for PTV2 (p < 0.01). The volume covered by the 105 % isodose was reduced
with IMRT compared with 3D-CRT by 17.6 % for PTV1 (p = 0.01) and 27.4
% for PTV2 (p = NS).
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10 1. 3DCRT vs. IMRT for MPM after EPP
An example of the dose distribution at the level of the isocenter for the
3D-CRT and IMRT plans is shown in Fig. 1.2. On these two slices, IMRT
displayed better coverage of the PTV2 (green structure). The heart dose and
lung dose were slightly larger than with 3D-CRT. Fig. 1.3 and Fig. 1.4 show
the mean DVH average for all the MPM patients for 3D-CRT (plain line)
and IMRT (dotted line). The DVHs were normalized to 55.9 Gy at 100 % of
the mean dose to the PTV1. A better coverage of the PTVs was observed
with IMRT, but a lower dose to the liver, lung, and contralateral kidney (or
heart) was achieved with 3D-CRT.
Figure 1.2: Isodose distribution of representative transverse slice (plan-
ning target volume 1 (PTV1) in red and PTV2 in green) for (Left) three-
dimensional conformal radiotherapy (3D - CRT) and (Right) intensity-
modulated radiotherapy (IMRT). Gantry angles for IMRT beams were 345˚ ,
30˚ , 80˚ , 140˚ , and 195˚ . Beam angle for 3D - CRT was 0˚ and 180˚ for pho-
tons and electrons, respectively. Green, brown, blue, and cyan isodose lines
represent 20 %, 50 %, 90 %, and 95 % of prescribed dose (55.9 Gy for IMRT
and 57.6Gy for 3D - CRT), respectively. Yellow isodose line represents 95
% of prescribed dose to PTV2 dose (45.5 Gy for IMRT and 45 Gy for 3D -
CRT).
1.4.1 Organs at risk
Both techniques were able to keep the maximal spinal cord dose to less than
its tolerance limits. A non significant reduction of 2.8 Gy to the maximal
dose was achieved with IMRT compared with 3D-CRT (p = NS), as indicated
in Table 1.2. The maximal spinal cord dose was kept to < 47 Gy for each
patient with both techniques.
The mean contralateral dose delivered to lung tissue was increased by
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Figure 1.3: Mean dose - volume histogram (DVH) of planning target vol-
ume 1 (PTV1) (blue), PTV2 (red), liver (orange), and lung (green). DVHs
normalized to 55.9 Gy at 100 % of mean dose to PTV1. Solid lines repre-
sent three-dimensional conformal radiotherapy (3D - CRT) plans, and dotted
lines represent intensity-modulated radiotherapy (IMRT) plans.
7.8 Gy (p < 0.01) and the volume receiving a dose > 13 Gy (or > 20 Gy)
increased by 20.5 % (or > 7.2 %) with IMRT (p < 0.01, or p < 0.01).
The mean heart dose increased with IMRT compared with 3D-CRT by
9.1 Gy, from 17.1 Gy to 26.2 Gy (p < 0.01). No difference was observed for
the heart volume receiving a dose > 45 Gy (Table 1.2).
The mean dose delivered to the contralateral kidney was reduced with
3D-CRT by 3.6 Gy from 4.1 Gy to 0.5 Gy (p < 0.01). No difference in
dose delivery > 15 Gy to the contralateral kidney was observed for 3D-CRT
and IMRT, nor was the difference in the mean dose or the volume of the
ipsilateral kidney receiving a dose > 15 Gy significant.
1.4.2 Patient outcome and toxicities
The clinical outcome of all 17 patients, treated with 3DCRT using photons
before February 2005 and with IMRT after February 2005 was analyzed.
At follow-up, 6 patients had died (mean time between treatment onset and
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Figure 1.4: Mean dose - volume histogram (DVH) of heart (blue), ipsilateral
kidney (red), contralateral kidney (orange), and spinal cord (green) for three-
dimensional conformal radiotherapy (3D - CRT) (solid lines) and intensity-
modulated radiotherapy (IMRT) (dotted lines).
death, 22.5 months). All had experienced disease recurrence before death.
Six additional patients experienced local failure. Local failure occurred after
a mean of 18 months (range, 14 - 29 months). Adverse events exceeding
Common Toxicity Criteria Grade 2 were observed in 2 patients, both of
whom had received IMRT.
One patient developed pneumonitis 2 weeks after RT was completed. He
was admitted to the intensive care unit and received oxygen for 5 days. He
had recovered completely within the next 2 weeks. The mean dose to the
lung was 8 Gy, comparable to the mean lung dose in all IMRT patients
(Table 1.2). However, the volume of the pleural cavity receiving > 50 Gy
was six times larger than average.
A second patient with severe post-RT toxicity was admitted to the hos-
pital with suspected pneumonitis 1 week after the end of RT. The mean lung
dose had been 10 Gy compared with a mean dose of 6.9 ± 1.4 Gy in the whole
cohort of patients treated with IMRT without complications. He died after
3 weeks of cardiopulmonary failure. The autopsy revealed chronic empyema
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and consolidative bacterial pneumonia, as well as residual mesothelioma in
the mediastinal region. The event was scored as a lung-associated adverse
event, Common Toxicity Criteria Grade 5.
The volume receiving ≤ 5 Gy (V5) in Patient 1 was 61 % and was 92
% in Patient 2. The volume receiving ≤ 20 Gy (V20) was 4.7 % in Patient
1 and 3.9 % in Patient 2. In contrast to the V20, the V5 in Patient 2
significantly exceeded the mean values (6.8 % ± 4.6 % for V20, range, 0.5
- 17 %; and 58 % ± 20 % for V5, range, 44 - 88 %) of the IMRT patients
without complications. The PTV2 in both patients was comparable to that
in the whole cohort; however, the high-dose area (PTV1) was significantly
greater in Patient 1 (Table 1.3).
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1.5 Discussion
Continuously improving technology have led to improved dose conformity
and increasing interest in integrating RT in the treatment concepts of MPM
[13, 14]. Because IMRT is an optimal technical approach for treating con-
cave regions with many critical and radiation-sensitive tissue structures in
close proximity to the targeted region, it seems especially well suited for the
treatment of MPM, especially because greater conformity has the potential
to improve the effect of RT [15]. However, more recently, IMRT for MPM
has come into discredit after the report of high rates of pneumonitis after
EPP. In a recently published series, 46 % of the patients died of pneumoni-
tis within a median of 1 month [16]. Thus, a prudent and well-optimized
treatment design with the most appropriate technology seems to be essen-
tial in the treatment of MPM patients with ionizing RT. How to optimize
and define dose-volume constraints to target volumes and OARs continues to
be debated, and the contralateral lung is of special concern if IMRT should
remain an option for postoperative RT for MPM.
The major advantage of 3D-CRT is that protection of contralateral lung
tissue is easy, because no photon beams penetrate the contralateral lung.
Comparing the mean dose and lung V5 and V20, 3D-CRT performs better
than IMRT. However, whether the greater dose delivered to the contralateral
lung necessarily results in a proportional increase in the risk of pneumonitis
remains to be proved.
In the present comparative technique study, the statistical analysis and
clinical follow-up, at least to some extent, have helped to judge the role of
IMRT. The pneumonitis rate for IMRT after EPP in our series seemed quite
high, with lung-associated toxicities in 2 (22 %) of 9 patients. These observa-
tions and the reported incidence of 10 % of lung toxicity for patients treated
to a mean lung dose of < 15 Gy reported by others highlight the need for
rigorous dose constrains [17, 18]. A recent report analyzing pneumonitis in-
cidents after IMRT showed that adherence to constraints that generally con-
sidered only the mean and maximal dose to the OARs might not be enough
and that the V5 might be a better predictor of pneumonitis than the mean
lung dose or the lung V20 [19]. As shown in Table 1.3, we did not observe
large differences in the V20 or mean dose between the 2 IMRT patients with
lung-associated toxicities and the other 7 IMRT patients. However, in the
patient who developed pneumonitis, the volume receiving the simultaneous
integrated boost was significantly greater (3,215 cm3 vs. 766 cm3). The pa-
tient who died of cardiopulmonary failure had had a significantly greater V5
of 92 % compared to a mean V5 of 58 % ± 20 % in the IMRT group without
complications. Wang et al. [20] proposed a cutoff of 40 % in their series to
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avoid lung toxicity. In present series, a cutoff of 50 - 60 % seems acceptable.
As indicated by the case of Patient 1, the total volume of the hemithorax
receiving > 50 Gy must also likely be weighed to properly estimate the lung
toxicity.
Although the present numbers were too low to allow a definite conclu-
sion, taking into account observations from other investigators, we propose
redefining the OAR constraints for IMRT to minimize the incidence of pneu-
monitis after IMRT. We recommend maintaining the mean lung dose as a
value for reporting and decision making and propose to limit it to 10 Gy to
lung tissue for IMRT. The V20 should be kept ≤ 10 %, if possible, and the
V5 should be ≤ 60 % and, if feasible, ≤ 50 %.
In the present series, all patients were treated with IMRT using a simul-
taneous integrated boost technique. This approach allowed us to deliver >
2 Gy/d to defined subregions of PTV2. More information and controlled
clinical experience concerning the tolerance of large volumes treated with a
simultaneous integrated boost is needed. At this point, we suggest reducing
the PTV1 (the volume that received ≤ 54 Gy in our series) to ≤ 750 cm3.
We estimate that by implementing these stringent constraints, serious lung
toxicities can be maintained at < 5 % and the incidence of fatal pneumonitis
counterbalanced [16].
The balance between toxicity and efficacy seems to be a determinant
for MPM treatment, because improved local tumor control after PEE is a
prerequisite for better survival rates. Thus, ”cold and hot spots” represent a
problem inherent to 3D-CRT. Matching of photons and electrons is difficult,
and poor matching would result in > 20 % dose inhomogeneity in the junction
area. In addition, because the spinal cord is blocked when the dose to it
reaches 45 Gy, insufficient dose delivery to the superior mediastinum has been
observed [21], resulting in underdosage to critical areas [11, 12]. Assuming
that homogenous high dose delivery reduces the risk of local relapse, IMRT
should be the preferential initial approach for adjuvant RT after EPP. Three-
dimensional conformal RT should only be used if IMRT techniques exceed
the toxicity constraints. Moreover, IMRT allows one to also escalate the dose
to the area of greatest risk with the best conformity using an simultaneously
integrated or sequential boost.
1.6 Conclusion
Both 3D-CRT and IMRT might be adequate techniques for the treatment
of MPM. In the present study, 3D-CRT and IMRT were both able to keep
the maximal and mean doses in the OARs to less than the reported critical
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levels. However, after preoperative chemotherapy and EPP, the dose con-
straints must be reduced to respect the specific case. An individualized use
of techniques respecting patient- and disease-specific features is the key for
optimal use of RT. Still, IMRT seems to be the superior technique to deliver
greater doses with better dose homogeneity, even though the larger doses to
the OARs, especially in the contralateral lung, must be taken into consider-
ation. Currently, we recommend constraints for the lung of 5 Gy delivered
to ≤ 60 %, with ≤ 50 % preferable, if possible, and a mean total lung dose
of ≤ 13 Gy, with <10 Gy, preferable, if possible.
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1.1 Abstract
To perform comparative planning for intensity-modulated radiotherapy
(IMRT) and proton therapy (PT) for malignant pleural mesothelioma af-
ter radical surgery.
Eight patients treated with IMRT after extrapleural pleuropneumonec-
tomy (EPP) were replanned for PT, comparing dose homogeneity, target
volume coverage, and mean and maximal dose to organs at risk. Feasibil-
ity of PT was evaluated regarding the dose distribution with respect to air
cavities after EPP.
Dose coverage and dose homogeneity of the planning target volume (PTV)
were significantly better for PT than for IMRT regarding the volume covered
by > 95% (V95) for the high-dose PTV. The mean dose to the contralateral
kidney, ipsilateral kidney, contralateral lung, liver, and heart and spinal cord
dose were significantly reduced with PT compared with IMRT. After EPP,
air cavities were common (range, 0 - 850 cm3), decreasing from 0 to 18.5
cm3/day. In 2 patients, air cavity changes during RT decreased the general-
ized equivalent uniform dose (gEUD) in the case of using an a value of < -10
to the PTV2 to < 2 Gy in the presence of changing cavities for PT, and to
40 Gy for IMRT. Small changes were observed for gEUD of PTV1 because
PTV1 was reached by the beams before air.
Both PT and IMRT achieved good target coverage and dose homogene-
ity. Proton therapy accomplished additional dose sparing of most organs at
risk compared with IMRT. Proton therapy dose distributions were more sus-
ceptible to changing air cavities, emphasizing the need for adaptive RT and
replanning.
1.2 Introduction
Malignant pleural mesothelioma (MPM) is an increasing health problem; it
has a high mortality rate, with a median survival of only 19 months and sur-
vival rates at 2 and 5 years of 38% and 15%, respectively [1–3]. Multimodal
strategies have been proposed owing to the inability of any single modality
to achieve satisfactory long-term survival rates. Currently, the combina-
tion of surgery, radiotherapy (RT), and pre- or postoperative chemotherapy
achieves best results if patients present with an adequate performance status
[4–7]. Definitive local control of MPM with ionizing radiation remains a ma-
jor challenge owing to the large C-shaped clinical target volume (CTV) and
the proximity to kidneys, spinal cord, liver, heart, and contralateral lung.
Conventional RT has shown its limitations, primarily due to the poor ra-
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diation tolerance of neighboring normal organs (organs at risk, OARs) [8],
and intensity-modulated RT (IMRT) has been evaluated for postoperative
RT [4, 9, 10]. However, the size of the target volumes has resulted in con-
siderable risks of toxicity to the lung. We have previously established the
feasibility and appropriateness of IMRT, achieving good planning target vol-
ume (PTV) coverage in comparison with three-dimensional conformal RT
(3D-CRT) [11]. Intensitymodulated RT is a valid treatment option as long
as dose to the healthy, contralateral lung tissue can be minimized. Because
of its beam characteristics, proton therapy (PT) has promising features for
postoperative RT, potentially minimizing toxicity to neighboring OARs.
In this study, we compared postoperative IMRT with PT, to define po-
tential advantages of each technique. A dosimetric evaluation based on dose
- volume histogram (DVH) analysis and dose - volume parameters was per-
formed. The goal was to define the benefit of PT compared with IMRT and
to estimate the technical feasibility of treating MPM with postoperative PT.
After extrapleural pleuropneumonectomy (EPP), the ipsilateral hemithorax
contains variable amounts of air cavities, which subsequently are replaced by
fibrous tissue. Special consideration was given to changes of the air cavities
during the postoperative RT period. Their impact on dose coverage of the
target volumes was estimated, and the accuracy of the two techniques was
defined.
1.3 Methods and Materials
Eight consecutive patients diagnosed with MPM and treated with preoper-
ative chemotherapy followed by EPP and IMRT between October 2004 and
June 2006 at the Zurich University Hospital (Zurich, Switzerland) were ret-
rospectively replanned with PT. The group consisted of 1 female patient and
7 male patients; 4 patients presented with right-sided MPM and 4 patients
with left-sided MPM. The median age was 58 years (range, 48 - 66 years).
The clinical results of these 8 patients have been reported previously. For
the purpose of the present analysis, all target and nontarget structures were
maintained as originally planned [11]. Two CTVs were defined [11]. The
first, CTV1, defined the boost volume covering the postoperative areas with
possible microscopic disease by means of submacroscopic spread not resected
or not accessible to resection, the area of highest risk for relapse as defined
by the surgeon, or areas of positive margins according to pathology report,
and the area of preoperative macroscopic tumor. The second, CTV2, was
determined by the field of surgery including the entire preoperative pleu-
ral and pulmonary structures and scars, including the drainage sites. The
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PTV1 (respectively PTV2) was constructed using the automated region ex-
pansion tools from CTV1 (respectively CTV2 without CTV1) by adding an
additional margin of 5 to a maximum 10 mm in all three spatial directions.
PT treatment
Since 1996 PT has been routinely used for deep-seated tumors at Paul Scher-
rer Institute (Villigen, Switzerland). Details of beam delivery, treatment
planning system, and procedures have been published previously [12]. Dose
calculation and optimization were performed using the planning algorithm
based on spot scanning [13].
All patients were planned with two fields. The first covered the PTV1
and PTV2 (45.5 Gy in 26 fractions) and the second covered only the PTV1,
applied as an integrated boost (55.9 Gy total dose in 26 fractions). Fraction-
ation was the same as for IMRT. Beam angles were patient specific and were
chosen to optimize the coverage of the target and the avoidance of OARs.
IMRT treatment
Seven radiation beams (6 MV) were used. The superior portion of the PTV
was treated with only three to four beams that did not pass through the
contralateral lung tissue, as recommended by Allen et al. [14]. The remain-
ing beams were restricted superiorly at the inferior level of the heart for
the left-sided cases and at the level of the liver for the right-sided cases.
Intensity-modulated RT patients were planed with 26 x 1.75 Gy (45.5 Gy)
to PTV2, including a simultaneously integrated boost of 26 x 2.15 Gy (55.9
Gy) to PTV1. Calculation and optimization were performed using an inverse
treatment planning system (HELIOS, Eclipse V8.5 with AAA 8.2.23 algo-
rithm; Varian Medical Systems, Palo Alto, CA). Treatments were delivered
on a 6-MV photon linear accelerator (Clinac 6EX; Varian Medical Systems)
equipped with a 120 dynamic multileaf collimator using the sliding windows
with a dose rate of 300 monitor units per minute.
Dose - volume constraints
The maximum dose to any part to of the spinal canal was kept below 50
Gy. The mean dose given to the heart was limited to < 40 Gy, and the
maximum heart volume receiving 45 Gy was kept to < 30 %. The mean
contralateral lung dose was limited to ≤ 8.5 Gy, in accordance with our
previous observations that patients receiving 6.9 ± 1.4 Gy did not experience
any pneumonitis as compared with patients with pneumonitis with a mean
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dose of 8.8 Gy (11). Not more than 10 % of the contralateral lung volume
was allowed to receive a dose ≥ 20 Gy. The mean dose to the liver was not
permitted to exceed 30 Gy. The mean dose to the kidneys was restricted to
≤ 12 Gy, and the volume of kidney receiving more than 15 Gy was kept to
< 20%.
Plan comparison
Dose - volume histograms were calculated for the PTVs and OARs for each
plan. For comparison purposes DVHs were normalized to the mean dose of
the PTV1 (55.9 Gy over 26 fractions). Target dose distribution was evaluated
according to the volume covered by 95 % (V95) and 105 % (V105) of the
prescribed dose. The doses to OARs were evaluated according to mean dose
and organ-specific tolerance levels, such as the volume covered by 15 Gy
(V15) for kidneys, dose to 2 % volume of the spinal cord (D2), V45 for heart,
and V5, V13, and V20 for contralateral lung [3, 15,16].
Air cavities
Air cavity changes within the ipsilateral hemithorax after pleuropneumonec-
tomy were measured as a function of time on various postoperative diagnostic
CT scans and the RT planning CT. Optimized plans with air cavities > 100
cm 3 were used to evaluate the effect of the variation of the air cavities on the
dose distribution by overwriting the density of the air cavity to 1 and recalcu-
lating the dose distribution. Evaluation of the variation of DVH parameters
was performed for PT and IMRT [17] for 2 patients: 1 with the largest and 1
with the smallest air cavity measured on the planning CT. The generalized
equivalent uniform dose (gEUD) was also calculated for both techniques and
for each structure [18].
Statistics
Statistical analysis was performed using a paired t test. The t - test and the
p - value were calculated with StatView 5.0.1 software. A p - value of < 0.05
was accepted as significant.
1.4 Results
An example of comparative treatment planning is shown in Fig. 1.1.
Intensity-modulated RT and PT covered the PTV1 and PTV2 by 95% of
the prescribed dose. The lung and the two kidneys received a larger dose
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with IMRT compared with PT. Fig. 1.1 also shows a rapid dose fall-off out-
side the PTVs for the PT plan.
Figure 1.1: Dose distribution in transverse planes for protons (right) and
intensity-modulated radiotherapy (left) at the axial level of kidney (top) and
lung (bottom). Curves are shown for the entire treatment to a total dose of
55.9 Gy to Planning Target Volume 1 (PTV1) (blue structure) and 45 Gy to
PTV2 (pink structure). The dark blue and pink isodose lines represent 95
% the prescribed dose to PTV1 (55.9 Gy) and PTV2 (45.5 Gy). The yellow,
cyan, light green, and dark green isodose lines represent 30 Gy, 20 Gy, 10
Gy, and 5 Gy, respectively.
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Target volumes
The average DVHs of IMRT and PT plans for targets and OARs are shown
in Table 1.1 and Fig. 1.2. The DVHs were normalized to 55.9 Gy at 100%
of the mean dose to PTV1. The DVH graphs for PTV1 are steeper with PT
than with IMRT, reflecting improved dose conformity and dose homogeneity
to the targets. When expressed as the parameter V95, the difference reached
significance only for PTV1 (p = 0.04). Indeed, V95 for PTV2 was 95.7 %
for PT and 92.0 % for IMRT (p = NS). For PTV1, V95 was 97.0 % for PT
and 95.4 % for IMRT (p = 0.04). The V105 for PTV1 was 3.2 % for PT and
4.0 % for IMRT, and for PTV2 (p = NS) was 31.2 % for PT and 30.2 % for
IMRT (p = NS).
Figure 1.2: Dose - volume histogram for Planning Target Volume 1 PTV1)
and PTV2 for intensity-modulated radiotherapy (IMRT, solid lines) and pro-
ton therapy (PT, dotted lines). The dose - volume histograms have been
normalized to 55.9 Gy at 100 % of the mean dose to PTV1.
Organs at risk
Comparison data for OAR are summarized in Table 1.1 and Fig. 1.3. Both
IMRT and PT were able to keep the maximum spinal cord dose below tol-
erance limits. A reduction by 7.2 Gy of the dose to 2 % of the spinal cord
volume was achieved with PT in comparison with IMRT (p = 0.03). The
volume of spinal cord receiving a dose between 0 and 40 Gy was reduced to
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a greater extent with PT compared with IMRT (Fig. 1.3).
Figure 1.3: (a - c) Dose - volume histogram of the contralateral lung,
spinal cord, liver, heart and the kidneys for intensity-modulated radiotherapy
(IMRT, solid lines) and proton therapy (PT, dotted lines).
The mean dose to the residual lung for IMRT was 4.6 Gy, 5.1 Gy for left-
sided tumor and 4.1 Gy for right-sided tumor (Fig. 1.3 a). The mean lung
dose decreased by 4.2 Gy with PT to 0.4 Gy (0.5 Gy for left-sided tumors
and 0.3 Gy for rightsided tumors) compared with IMRT. The lung volume
receiving a dose > 5 Gy, > 13 Gy, or > 20 Gy decreased by a factor of 18
(from 27.5 % to 1.5 %, V5), 10 (from 7.1 % to 0.7 %, V13), and 6 (from 2.9
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% to 0.5 %, V20) with PT compared with IMRT (p < 0.01).
Dose - volume histograms for the heart are displayed in Fig. 1.3 a. The
mean dose delivered to the heart decreased with PT by a factor of 4.2 in
comparison with IMRT, from 25.0 Gy to 6.0 Gy (textitp < 0.01). The dose
to the heart for leftsided tumors was 30.4 Gy for IMRT and 9.7 Gy for PT
and for right-sided tumors was 19.5 Gy (IMRT) and 2.3 Gy (PT). The part
of the heart receiving a dose > 45 Gy was located in close proximity to PTV.
No differences were observed on the heart volume receiving a dose > 45 Gy
(2.1 % for PT and 6.8 % for IMRT). However, PT spared to a greater extent
the heart volume at all levels below 45 Gy.
The mean liver dose was 6.7 Gy for left-sided tumors and 19.7 Gy for
right-sided tumors for IMRT. The mean liver dose decreased by a factor
of 3.6 with PT, from 13.2 Gy to 3.7 Gy (7.1 Gy for left-sided tumor and
0.3 Gy for right-sided tumor) (p = 0.01). Eighty percent of the liver volume
(D80) received < 1 Gy with PT, whereas D80 increased to 26.5 Gy for IMRT
(Fig. 1.3 c).
The dose to the contralateral kidney was minimal with PT (mean dose
of 0.1 Gy), whereas IMRT delivered a mean dose of 2.7 Gy (p < 0.01).
The maximal contralateral dose was reduced by a factor of 37, from 7.5 Gy
for IMRT to 0.2 Gy with PT. The mean dose to the ipsilateral kidney was
decreased by a factor of 1.7, from 11.8 Gy for IMRT to 7.0 Gy with PT (p
= 0.02). A decrease by 10.2 % of the ipsilateral kidney volume, from 27.6 %
with IMRT to 17.4 % with PT receiving a dose >15 Gy, was observed with
PT (p = NS) ( Table 1.1).
Air cavities
An example of air cavity changes after EPP on a transverse and sagittal
section is displayed in Fig. 1.4. The variation of air cavity volumes in the
operated hemithorax as a function over time between surgery and postop-
erative CTs is displayed in Fig. 1.5 for all patients. The points have been
fitted with an exponential function:
V = 684exp(− t
30.7
) (1.1)
were V is the volume in cm3, t is the number of days from the operation.
The median time between the operation and the RT planning CT was 68
days (range, 54 - 293 days). A median period of 18 days (range, 13 - 22
days) was observed between the dedicated planning CT and the first RT
treatment. Air cavity changes regressed with time from surgery. After 80
days a mean air cavity of 50 cm3 was observed, and after 100 days the mean of
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the volume of the air cavities was 26 cm3. All air cavities resolved within 293
days, although the dynamics of the air cavities depended on the individual
patient. The fastest volume changes of the air cavity were observed in Patient
8, with a reduction of 222 cm3 within 12 days (18.5 cm3/day).
Figure 1.4: Computed tomography of a right-sided malignant pleural
mesothelioma patient 7 days (top) and 47 days (bottom) after extrapleu-
ral pleuropneumonectomy. Initial air cavity of 850 cm3 on Postoperative
Day 7 was reduced to 340 cm3 by Day 47. Right: transverse image planes;
left: sagittal planes.
The influence of the variation of the cavities on the dose distribution was
studied in detail for 2 patients, representing either the smallest or largest
air cavity on planning CT. The size of the initial air cavity was 380 cm3
in Patient 1 and 160 cm3 in Patient 4 (Fig. 1.5). The mean dose to PTV1
and PTV2 decreased by < 1 Gy for both patients and both techniques. The
volume covered by 95 % of the prescribed dose decreased by 0.2 % for PT
and 1.6 % for IMRT for PTV1 and by 3.2 % for PT and 0.4 % for IMRT for
PTV2 for Patient 4. The difference of the mean dose to liver, contralateral
lung, and kidneys, as well as the maximum dose to the spine, was within 0.5
Gy for PT and IMRT.
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Figure 1.5: Variation of the air cavity size as a function of time. Day 0 =
date of surgery (extrapleural pleuropneumonectomy). Points with a circle
represent the CT scan used for the radiotherapy treatment. The averaged
extrapolated data are shown with the interrupted red line.
In contrast to the V95 % evaluation of the target volumes, gEUD analysis
proved more sensitive for pinpointing underdosed PTV2, especially for small
cold spots. The gEUD is a function depending on the parameter a, which
is a tumor parameter that describes the dose volume effect. For a = 0, the
EUD is equal to the geometric mean dose. When a = -∞, the EUD is equal
to the minimal dose. Because the actual value of a to calculate the gEUD
to the target volumes is unknown, we evaluated the gEUD for a values from
-1 to -20 for PT. The gEUD for IMRT was hardly affected by the changes
and IMRT of tissue densities (air cavity). For PT, the gEUD dropped to <
2 Gy for Patients 1 and 4, compared with 40 Gy for IMRT (Fig. 1.6). The
gEUD was also calculated for PTV1 and the OARs for PT and IMRT. No
significant difference was observed when comparing plans with or without
cavities if air cavities were avoidable using an optimal beam arrangement.
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Figure 1.6: Generalized equivalent uniform dose (gEUD) for Planning Target
Volume 2 (PTV2) as a function of the parameter a for a patient with and
without air cavity. The gEUD for the PTV2 without air cavities (solid lines)
and with air cavities (dotted lines) for Patient 1 (blue and yellow curves) and
Patient 4 (red and green curves). The blue and red curves are for intensity-
modulated radiotherapy (IMRT), and the yellow and green curves are for
proton therapy (PT). 1 = Patient 1 with air cavity planned with IMRT; 2
= Patient 1 without air cavity planned with IMRT; 3 = Patient 1 with air
cavity planned with PT; 4 = Patient 1 without air cavity planned with PT;
5 = Patient 4 with air cavity planned with IMRT; 6 = Patient 4 without air
cavity planned with IMRT; 7 = Patient 4 with air cavity planned with PT;
8 = Patient 4 without air cavity planned with PT.
1.5 Discussion
Significant improvements in dose conformity have been achieved with IMRT.
In 2003 preliminary data on IMRT for the treatment of MPM after EPP were
reported, and better local control than with conventional techniques was sug-
gested [4]. Others have indicated a limitation of IMRT in MPM patients due
to the risk of pneumonitis [11, 19]. Severe lung complications in MPM pa-
tients after IMRT, including radiation-related deaths from pneumonitis in 10
% or more of patients treated with IMRT, have been reported [11, 19, 20].
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Even with optimized IMRT, the contralateral lung will always receive an exit
dose, resulting in low dose to a large volume of lung, and helical tomother-
apy has been recently reported to result in low mean dose delivered to the
contralateral lung [21]. Excessive dose to the contralateral lung rarely occurs
with 3D-CRT [11,22]. However, both techniques have their limitations: dose
coverage is improved with IMRT compared with 3D-CRT at the expense of
a higher dose to OARs [11].
Proton therapy is able to accomplish both goals, namely target cover-
age and low dose to OARs. Protons, unlike photons, deposit most of their
energy at a specific energy-dependent depth (Bragg peak). Furthermore,
scatter from the irradiated cavity to healthy lung tissue can be reduced with
protons up to a factor of 10, especially if using spot scanning technology
[23]. Intensity-modulated RT and PT beam angles were chosen specifically
to limit dose. However, the contralateral lung dose remained significant for
IMRT at a mean of 4.6 Gy; PT kept this value to < 1 Gy because of the lack
of exit dose. The reduction in contralateral lung dose achieved with PT is
expected to significantly reduce any risk of pneumonitis [15,16,20] compared
with IMRT [11, 19]. Furthermore, the exact dose in the lowdose region may
be underestimated for IMRT owing to inaccuracy of the treatment planning
system to adequately simulate the microleaf collimator. Dose underestima-
tion for the healthy lung has been reported as high as 25 % for V5 and 7
% for V10 for MPM patients [24]. Taking into account inaccuracies, the
difference between PT and IMRT could be even larger than reported here.
Proton therapy improved target dose coverage for all patients; this difference
was statistically significant for PTV1. Proton therapy also performed con-
sistently better for each OAR. Both IMRT and PT were safe for the spinal
cord, keeping D2 to < 40 Gy for each patient. Proton therapy reduced the
D2 of the spinal cord by 7.2 Gy. Dose reduction to the spinal cord, without
compromising the dose in the target volumes, could be especially useful if
incomplete resection is suspected at the vertebro-pleural recess. Side effects
during or afterward might be reduced or the dose saved in case of salvage.
Another aspect of dose reduction in nontarget tissues is dose escalation to
the target structures.
We investigated the impact of postoperative air in the chest after EPP.
Air volume changes during RT were considerable, and alterations in patient
anatomy and modified target coverage and dose given to OARs need to be
considered [25–27]. The difference of dose to the targets between the plans
with and without air cavities showed reduced target coverage, a decrease of
V95 by 1.6 % and 0.2 % for PTV1 and 0.4 % and 3.2 % for PTV2 for IMRT
and PT, respectively. The gEUD to the target changed only for PTV2. The
values of gEUD with filled air cavities had a significant reduction of dose to
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PTV2, reducing dose to < 2 Gy. This reduction is due to the quality of the
proton dose fall-off. When the air cavities are replaced by liquid over time,
the depth of the dose maximum (Bragg peak) is pulled upstream, removing
the dose downstream, in the deepest part of the target. Alternatively, avoid-
ing air cavities along the proton beam track is likely to avoid underdosage,
and flexible gantry angles potentially improve on dose delivery. However,
it is important to compensate for anatomic changes and to reassess all air
cavities with adaptive planning to ascertain proper dose delivery. Although
photons as provided by multiangle IMRT are subject to loss of dose to target
volumes in the presence of air - liquid surfaces, the impact is far less promi-
nent than with singleangle proton beams. The difference of dose, as well as
the gEUD, to the OARs did not seem to be relevant (<0.5 Gy) when air cav-
ities were replaced with liquid. To avoid these dose variations, a delay of 100
days between EPP and the RT CT would decrease by 75 % the number of
patients with residual air cavities. However, a prolonged delay of starting RT
after EPP would likely reduce the chance for successful tumor control [28].
Therefore, repetitive on- or off-line replanning (e.g., using an on-board cone-
beam CT system to evaluate air cavities periodically and adapt treatment)
is recommended [29,30].
1.6 Conclusion
Proton therapy seems to be a superior technique to minimize the dose to
all OARs and to result in better coverage of the target volumes. Clinical
validation is mandatory. The major drawback is that protons seem highly
sensitive to changing air cavities, requiring follow-up CTs during treatment
to evaluate changes of cavities. Beam angle adaptation and replanning might
be necessary to ascertain optimal dose delivery.
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2 1. IMRT and VMAT for mesothelioma treatment
1.1 Abstract
Radiotherapy reduces the local relapse rate after pleuropneumonectomy
of malignant pleural mesothelioma (MPM). The optimal treatment tech-
nique with photons remains undefined. Comparative planning for intensity-
modulated radiotherapy (IMRT) and volumetric-modulated arc therapy
(VMAT) was performed. Six MPM patients with significant postoperative
intrathoracic air cavities were planned with IMRT and VMAT. A dose com-
parison for the targets and organ at risks (OAR) was performed. Robustness
was assessed in respect to the variation of target dose with change in vol-
ume of air cavities. VMAT reduced the dose to the contralateral lung by
reducing the volume covered by 13 Gy and 20 Gy by a factor 1.8 and 2.8,
in respect to IMRT (p = 0.02). Dose distribution with VMAT was the most
stable technique in regard to postsurgical air cavity variation. For IMRT,
V90, V95, and the minimal target dose decreased by 40 %, 64 %, and 12 %
compared to 29 %, 47 %, and 7 % with VMAT when air cavity decreased.
Two arcs compared to one arc decreased the dose to all the organs at risk
(OAR) while leaving PTV dose coverage unchanged. Increasing the number
of arcs from two to three did not reduce the dose to the OAR further, but
increased the beam-on time by 50 %. Using partial arcs decreased the beam-
on time by 43 %. VMAT allows a lower lung dose and is less affected by the
air cavity variation than IMRT. The best VMAT plans were obtained with
two partial arcs. VMAT seems currently the most suitable technique for the
treatment of MPM patients when air cavities are remaining and no adaptive
radiotherapy is performed.
1.2 Introduction
Malignant pleural mesothelioma (MPM) is an aggressive tumor with a high
mortality rate and a survival rate of 38 % after two years and 15 % after
five years [1]. The role of RT after extrapleural pneumonectomy (EPP) is
to reduce local failure [2, 3]. The dose to the hemithorax is typically limited
to 45 Gy with a boost to 55 Gy [2, 4] due to the adjacent dose limiting
structures, such as the lung, kidney, spinal cord, liver, and heart. However,
the tumor control rates after EPP, chemotherapy, and radiotherapy remains
poor [5]. In order to enhance tumor control, dose escalation is an option if
dose conformity is improved (e.g., proton therapy has been proposed for dose
escalation due to the low dose delivered to the contralateral lung, heart, and
kidney) [5]. However, access to proton therapy (PT) remains limited and
proton techniques are hampered by postsurgical air cavities. After EPP, the
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ipsilateral hemithorax contains variable amounts of air, which subsequently
are replaced by fibrous tissue. These cavities decrease over time, reducing
drastically the dose to the target for PT which would decrease tumor control
and counteract any potential benefit of an eventual dose escalation.
In this study, an evaluation of a new RT technique, volumetric-modulated
arc therapy (VMAT) was performed for the treatment of MPM patients.
The optimal number of arcs and degree of rotation were evaluated for the
treatment of MPM patients with VMAT. Postoperative IMRT and VMAT
were compared in order to define potential advantages of each technique:
dosimetric benefit and treatment time. Another goal was to evaluate the
dose variation of VMAT and IMRT in respect to the variation of air cavities
in the resected lung, and to evaluate for which air cavity variation adaptive
planning is required. This was evaluated in respect to the change of dose in
the target.
1.3 Methods and materials
etween 2004 and 2011, 16 patients diagnosed with MPM were treated with
external radiotherapy at the Zurich University Hospital, Switzerland. All
of these patients received preoperative chemotherapy followed by extrapleu-
ral pleuropneumonectomy (EPP) and modulated radiotherapy. Six of 16
patients had air cavities exceeding 100 cm3 when the treatment planning
computer tomography (CT) was performed and were selected for the present
study. All CTs have been performed in supine head-first position. Five pa-
tients were male and one female. Five patients presented with right-sided
MPM and one patient with left-sided MPM. Two of these six patients were
treated with VMAT and four patients were treated with IMRT. All patients
were planned with IMRT and VMAT, two patients prospectively and four
patients retrospectively. The comparison between IMRT and VMAT was
based on dose distribution, treatment time, and robustness of the techniques
in respect to the effect of variation of the air cavity on the dose distribution.
Target volume definition was obtained as described previously in detail
[5]. All patients were planned and treated with 26 x 1.75 Gy (45.5 Gy) to the
planning target volume two (PTV2) including a simultaneously integrated
boost of 26 x 2.15 Gy (55.9 Gy) to the PTV1. Due to the difficulty of the
algorithm to optimize correctly the dose in air cavity, a PTV2* was defined
for evaluation purpose only as PTV2 without air cavity.
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1.3.1 IMRT and VMAT treatment
The technique used for IMRT was described previously [3] and followed the
recommendation from Allen [6].
The VMAT plans were performed with two clockwise arcs of 205˚ ranging
from 180˚ to 25˚ for right-sided tumors and from 335˚ to 180˚ for left-sided tu-
mors. The isocenter was placed in the middle of the PTV2. The partial-arc
technique was used in order to avoid entrance dose to the contralateral lung.
The collimator angles were set to 355˚ and 5˚ .
The patient with the PTV volume closest to the mean PTV volume of
all six MPM patients was chosen to assess the optimal number of arcs and
the rotation angle required to treat MPM patients. Plans with one, two, or
three full arcs (360˚ ) or partial arcs (205˚ ) were performed in order to assess
the optimal number of arcs and gantry rotation. When one arc was used,
the collimator angle was set to 5˚ . If a second arc was added (respectively a
third arc), the collimator angle was set to 355˚ (respectively 10˚ ).
1.3.2 Dose calculation and delivery
Calculation and optimization were performed for IMRT and VMAT using an
inverse treatment planning system (HELIOS, Eclipse V8.9 with AAA 8.9.08
algorithm, Varian Medical System, Palo Alto, CA). One patient was calcu-
lated with Acuros XB (Varian Medical System) in order to quantify the dose
distribution difference between one of the most advanced algorithm (Acuros)
and AAA, the algorithm used clinically [7]. Treatments were delivered on a
6 MV photon linear accelerator (Trilogy, Varian Medical Systems) equipped
with a Millennium multileaf collimator with 120 leaves. Patient positioning
was verified with either cone-beam CT (CBCT) or with two orthogonal kV
images.
Pretreatment dose verification was performed with a cylindrical PMMA
phantom having two perpendicular planes of 1069 diodes (Delta4; ScandiDos
Inc., Uppsala, Sweden). The verification of the plan had to reach a gamma
score of 95 % (3 % dose difference, 3 mm distance to agreement) before
patient irradiation. .
1.3.3 Dose volume constraints, plan and treatment
comparison
The dose constraints chosen were published previously [3] and are summa-
rized in Table 1.1. DVHs were calculated for the PTVs and OARs for each
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plan. Target dose distributions were evaluated according to the volume cov-
ered by 80 %, (V80), 85 % (V85), 90 % (V90), 95 % (V95) and 105 %
(V105) of the prescribed dose and to the minimal dose (D99) and maximal
dose (D1). The dose to OARs were evaluated according to mean dose, and
organ-specific tolerance levels such as the volume covered by 15 Gy (V15)
for kidneys, maximal dose to the spinal cord (D1), and V5, V13, and V20
for contralateral lung [1, 8, 9].
The treatment time, as well as the number of monitor units needed for
one fraction, were evaluated for IMRT and VMAT.
1.3.4 Air cavities
Air cavity volume changes within the ipsilateral hemithorax following pleu-
ropneumonectomy were measured as a function of time on various postop-
erative control computed tomographies (CT), RT planning-CT. and CBCT
[3]. The air cavity volumes ranged from 150 cm3 to 1276 cm3. The axial,
sagittal, and coronal views from the patients are displayed on Fig. 1.1. The
evaluation of the variations of D1, D99, V80, V85, V90, V95, V100, and
V105 with decrease of the air cavity volumes for the PTV1 and PTV2* were
performed for IMRT and VMAT. Therefore, the dose distribution calculated
on the planning CT was recalculated on all control CTs. When cone-beam
CTs or lateral images where available, the resected lung density of the plan-
ning study was modified in respect to these images. The effect of the air
cavity decrease on the OARs was small as observed in this study and also
on a previous study [3]. Therefore, the OAR dose fluctuation and air cavity
variation are not reported in this study.
1.3.5 Statistics
Statistical analysis was performed using a paired t-test. A p-value of < 0.05
was accepted as significant.
1.4 Results
The dose distribution calculated with AAA or Acuros, showed similar results.
Indeed, V90, V95, as well as the mean dose for the targets and air cavities,
where within 1 %. Therefore, all data presented were calculated with the
algorithm, AAA, used clinically.
A typical dose distribution for IMRT and VMAT are displayed in the
axial, sagittal, and coronal view for one patient on Fig. 1.2. IMRT and VMAT
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covered PTV1 with the 95 % of the prescribed dose, but the PTV2* was
partially underdosed with IMRT. The dose to the spinal cord, contralateral
lung, and heart is equivalent for this patient. A larger posterior dose from
the PTV1 is observed for IMRT. This ”hot spot” results from the intersection
of the three dorsal fields.
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Figure 1.1: Air cavities remaining in the resected lung at the date of the
planning CT in the axial (left images), coronal (middle images) and sagittal
(right images) view. Five patients had a right sided MPM (a, b, c, e and f)
and one patient had a left sided MPM (d). The volume of the air cavities
are 150 cm3 (a), 225cm3 (b), 243 cm3 (c), 276 cm3 (d), 379 cm3 (e) and 1276
cm3 (f).
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1.4.1 Target volumes
DVH parameters for IMRT and VMAT plans for targets and OARs are sum-
marized in Table 1.1. These parameters where calculated for VMAT using
two partial arcs of 205˚ . The dose distribution was normalized to 55.9 Gy at
100 % of the mean dose to the PTV1. The difference in dose homogeneity,
minimal dose and maximal dose in the PTV1 for IMRT and VMAT was
small and not significant. Indeed, the mean difference for V95, V105, D1,
and D99 was within 1.8 % (p not significant). Regarding the PTV2*, VMAT
increased the V95 by 0.5 % and decreased V105 by 1.8 % (p not significant).
V80, V85, and V90 for PTV2* were always larger than 98 % for each IMRT
and VMAT plans. Therefore, these values were not displayed on Table 1.1.
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1.4.2 OAR
Comparison data for OAR are summarized in Table 1.1. Both, IMRT, and
VMAT were able to keep the dose to the OAR below the constraints fixed
in Table 1.1, except for the ipsilateral kidney. The mean dose and V15 for
the ipsilateral kidney, which is surrounded by the target, could not be kept
below 12 Gy and 20 %.
The mean ipsilateral kidney dose and V15 were 12.4 Gy and 28.2 Gy
(respectively) for IMRT, and 11.9 % and 31.5 % (respectively) for VMAT (p
= 0.25 and 0.06). It was not possible to keep these values below our objectives
of 12 Gy and 20 % due to the target surrounding the ipsilateral kidney. For
the contralateral kidney, both techniques were able to keep the mean dose far
below the constraints of 12 Gy (3.6 Gy for IMRT and 3.8Gy for VMAT, p =
0.47), and V15 was kept at 0 % for IMRT and VMAT. The contralateral lung
V5 increased by 8.4 % with VMAT in respect to IMRT, but the mean dose,
as well as V13 and V20 to the contralateral lung, were reduced by 0.6 Gy, 2.7
%, and 1.6 % (respectively) with VMAT. The difference reached significance
only for V13 and V20 (p = 0.02). The maximal spinal cord dose as well as
the mean liver dose for IMRT and VMAT were very close to each other and
the difference was not significant (p = 0.42 and 0.19).
1.4.3 MU and Treatment time
The mean number of monitor units was drastically reduced from IMRT to
VMAT by a factor 4.2 from 2080 ± 414 MU for IMRT to 485 ± 82 MU for
VMAT in order to deliver 2.15 Gy (p<0.01). The time required to deliver the
plan was around 10 minutes for IMRT and 4 minutes for VMAT. The beam-
on time for VMAT depends on the number of monitor units, dose rate, gantry
angle rotation, and gantry rotation speed. For all the plans performed with
VMAT, the gantry rotation speed was always at its maximal speed, 4.8˚ /s,
and the dose rate was modulated accordingly. Therefore, in our case, the
monitor units were not affecting the treatment time for the delivery of the
VMAT plans, but only the gantry rotation angle determined the beam-on
time.
1.4.4 Air cavities
Air cavities on the planning CT are displayed in Fig. 1.1. The initial air cavity
measured on the planning CT ranged from 150 cm3 to 1275 cm3. The air
cavity remaining after EPP shrinks with time to disappear completely. The
volume decrease can reach 220 cm3 in 12 days [3]. The decrease of V80, V85,
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V90, V95, V100, V105, D1, and D99 in planning situation with air cavities
are displayed on Fig. 1.3 and Fig. 1.4. IMRT and VMAT were not affected by
the change of the air cavity volumes in respect to V80. V85 decreased only
for IMRT when the air cavity variation was larger than 880 cm3. A decrease
up to 10.2 % for V85 was observed when the air cavity volume decreased by
1276 cm3. IMRT (respectively VMAT) V90 decreased when a variation larger
than 310 cm3 (respectively 610 cm3) was observed. The decrease of V90 was
up to 40.3 % for IMRT and 9.4 % for VMAT. A reduction of V95 for IMRT
and VMAT was observed for air cavity variation > 200 cm3. The decrease
of V95 could reach 64.4 % for IMRT and 29.2 % for VMAT. A decrease >
28 % for V95 is observed for IMRT in comparison to VMAT for air cavity
reduction larger than 311 cm3. Concerning PTV2, similar results as for
PTV1 have been observed when air cavity shrinks. V80 (respectively V85)
was not affected by a change of air cavity for IMRT (respectively VMAT).
Decrease larger than 20 % of V100 was observed when air cavity decreases
by 300 cm3 and 600 cm3 for IMRT and VMAT, respectively.
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14 1. IMRT and VMAT for mesothelioma treatment
Figure 1.4: Impact of the air cavities volume variation on the minimal and
maximal dose of PTV1 for IMRT and VMAT. The PTV1 minimal dose
(D99), respectively maximal dose (D1) is defined as dose received by 99
%, respectively 1 %, of the PTV1 volume. Data are derived from 6 MPM
patients with air cavities larger than 100 cm3.
A decrease of V100 and V105 was observed for IMRT and VMAT even for
small volume shrinking (150 cm3). This decrease reached 100 % for IMRT
when the air cavity volume decreases by 310 cm3 for V105 and 842 cm3 for
V100. For VMAT, a maximal decrease of 47 % for V100 and 72 % for V105
was observed.
The minimal dose and the maximal dose in the PTV1 as a function of
the variation of the air cavities are displayed in Fig. 1.4. The minimal dose
for IMRT decreased up to 12.4 % and up to 6.9 % for VMAT. The decrease
of the maximal dose was more pronounced for IMRT with a decrease up to
6.1 % and 1.7 % for VMAT.
1.4.5 Optimal number of arcs for VMAT plans
DVH parameters and monitor units for plans performed with one, two, and
three partial and full arcs are displayed in Table 1.2. These parameters have
been calculated for the patient having the PTV volume closest to the mean
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PTV volume. When one arc is used, a full rotation showed better results
than a partial rotation. Indeed, the V95 for the PTV1 was increased from
93.3 % to 95.6 % and V105 was decreased by 4.5 % with the full-arc rotation.
All OARs had a lower dose with the full-rotation arc, except for the maximal
dose to the spinal cord. If two arcs are used instead of one arc, V95 and V105
for the PTV were slightly improved and the dose to all OARs was drastically
reduced. The same observation was seen for the dose to the left and right
kidneys, liver, heart, and maximal dose to the spinal cord. The difference
between two arcs of 205˚ and two arcs of 360˚ was very small, with a small
improvement for the partial arcs in respect to the lung dose. If the number
of arcs is increased from two to three, there is a small benefit for V95 for the
PTV1. For the OAR, slight deviation was observed between two and three
partial- or full-arc rotation.
16 1. IMRT and VMAT for mesothelioma treatment
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The number of monitor units increased with the gantry rotation angle.
The monitor units ranged from 251 for a partial arc (205˚ rotation) to 708
for three full rotations (3 x 360˚ ). The difference of beam-on time between
the partial-arcs rotation and full-arc rotation was always 43 % in favor of
the partial-arc rotation. Indeed, the gantry rotation speed was always at its
maximal velocity, 4.8˚ /s, during the rotation of the arcs for each plan. There-
fore, the treatment time was not affected by the number of monitor units but
was proportional only to the rotation angle performed by the gantry.
1.5 Discussion
Improved technologies enhance dose conformity, and avoiding dose delivery
to critical structures has opened ways to treat complex oncological situa-
tions, such as MPM after EPP [10,11]. The RT treatment of MPM patients
is commonly performed with IMRT, with improved dose conformity and ho-
mogeneity to the targets in comparison with 3D conformal radiotherapy (3D
CRT) [5]. However, a major drawback of IMRT is the treatment time. Treat-
ment delivery is time-consuming due to the large number of fields which are
usually doubled due to split field technologies. Furthermore, a large number
of MUs is needed (2080 ± 414 MU). The introduction of VMAT reduced
the number of MUs by a factor of 4.2, reducing the treatment time from 10
minutes to 4 minutes. As reported previously [10], the decrease in treatment
time reduces patient motion during the treatment delivery and thus results
in greater agreement between the dose planned and dose delivered. This re-
duction in treatment time will decrease the time in which the patient has to
stay in an uncomfortable position on the back with arms above the head.
Concerning the dose to the OAR, no major differences were seen between
IMRT and VMAT, except for the lung. However, a reduction by a factor
of 1.8 and 2.8 for V13 and V20, respectively, for the lung was observed for
VMAT. This reduction of lung dose could decrease the risk of complication,
such as radiation-induced pneumonitis, where rates larger than 40 % have
been reported [11].
The dose conformity and homogeneity were not statistically different for
IMRT and VMAT. This is in agreement with previously published data [10].
Nevertheless, the small difference between IMRT and VMAT concerning the
target coverage and dose homogeneity on the planning CT does not imply an
identical delivery of dose to the target during all treatment sessions. Indeed,
air cavities remain in the chest after EPP. The air volume change during
RT can be considerable [3] This will have a direct impact on DVH param-
eters for IMRT and VMAT plans. Indeed, when reduction > 311 cm3 of
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the air cavity occurs, V95-V105, D1, and D99 are drastically modified. The
decrease of dose to the target can even reach 100 % for IMRT for V100 and
72 % for VMAT. The reason comes from the fact that the air cavity volumes
are always located on the ventral part of the resected lung. When the lung
cavity is replaced by serofibrous tissue during treatment, dose distribution
delivered with photons coming from the anterior direction will be most af-
fected, and the proportion of photons coming from the anterior direction is
more pronounced for IMRT than for VMAT. Therefore, a larger decrease of
dose for IMRT in the target occurs when the air cavities disappear than for
VMAT.
The overall decrease of dose coverage with decrease of air cavity is not a
monotonic function, as observed on Fig. 1.3. These data are displayed for six
MPM patients with air cavity larger than 100 cm3. The change of PTV1 dose
coverage will be strongly influenced by the location of the PTV1. Indeed,
the higher the proportion of photons depositing energy in the PTV1 going
through air cavity before the PTV1, the higher the PTV1 will be affected by
a change of air cavity.
A special concern comes with the decrease of air cavity volumes >200
cm3 reducing dose homogeneity of target volumes (Fig. 1.3 b). Small air
cavity decrease (<200 cm3) will impact only on the high dose in the PTV
(V105 and V100). The minimal dose and V95 will decrease by less than 2
%.
If the air cavity volume decreases > 200 cm3 compared to the planning
situation, cold spots will appear in the target volume. Monitoring of air
cavities can be achieved with two orthogonal kV images taken prior RT or
with a CBCT. When an air cavity volume decrease larger than 200 cm3
is observed, a control planning CT might be helpful in order to assess the
impact on the dose variation and the need for an eventual new treatment
plan.
The dose distribution can be affected by the number of beams. Regarding
VMAT, an improvement of the dose distribution was observed when two arcs
are used instead of one arc. However, increasing the number of arcs from
two to three did not lead to any further improvement for partial- or full-
arc rotation. When two arcs are chosen, partial-arc techniques harbor the
advantage to avoid dose delivery to the remaining lung, and the beam-on
time can further be reduced by more than 40 % compared with the full-arc
rotation. Therefore, two partial arcs seem to be most suitable in respect to
treatment time and dose distribution.
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1.6 Conclusion
VMAT using multiple partial arcs enhances the treatment quality with pho-
tons when compared to IMRT by reducing the dose of ionizing radiation to
the remaining lung while saving treatment time and integral dose. VMAT
dose distributions are less susceptible to changing air cavities than IMRT. It
is recommended that patients having air cavity variation exceeding 200 cm3
be monitored attentively in order to consider adaptive replanning in case of
structural changes during treatment.
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2 1. Clinical outcome for MPM after HCRT
1.1 Abstract
Radiotherapy (RT) is currently under investigation as part of a trimodality
treatment of malignant pleural mesothelioma (MPM). The introduction of
highly conformal radiotherapy (HCRT) technique improved dose delivery
and target coverage in comparison to 3-dimensional conformal radiotherapy
(3DCRT). The following study was undertaken to investigate the clinical
outcome of both radiation techniques.
Thirty-nine MPM patients were treated with neoadjuvant chemotherapy,
extrapleural pneumonectomy (EPP) and adjuvant RT. Twenty-five patients
were treated with 3DCRT, and 14 with HCRT (Intensity modulated radio-
therapy or volumetric modulated arc therapy). Overall survival, disease free
survival, locoregional recurrence and pattern of recurrence were assessed. A
matched pair analysis was performed including 11 patients of each group.
After matching for gender, age, histology, tumour stage and resection
status, HCRT seemed superior to 3DCRT with a local relapse rate of 27.3 %
compared to 72.7 % after 3DCRT (p=0.06). The median time to local relapse
was increased by 49 % with HCRT in comparison to 3DCRT from 10.9 ±
5.4 months to 16.2 ± 3.1 months (p=0.06). The median overall survival was
22.3 ± 15.3 months for HCRT and 21.2 ± 9.2 months for 3DCRT (p=0.57).
Recurrence analysis showed that in-field local relapses occurred in previously
underdosed regions of the tumor bed in 16 % of patients treated with 3DCRT
and in 0 % of HCRT patients.
The use of HCRT increases the probability of local control as compared
to 3DCRT by improving target volume coverage. HCRT does not improve
overall survival due to high rates of distant recurrences.
1.2 Introduction
Malignant pleural mesothelioma (MPM) is a rare and aggressive malignancy
associated with poor prognosis. Although MPM is often initially confined to
the hemithorax, it has a high potential for metastatic spread in the course of
disease [1]. The mainstay of treatment is surgery consisting of either pleurec-
tomy/decortication (PD) or radical extrapleural pneumonectomy (EPP) in
combination with cisplatin/pemetrexed and, in selected cases, postoperative
radiotherapy [2–5]. The rationale to apply postoperative radiotherapy after
EPP has been the high rate of local recurrence after EPP alone of about 40
% [6].
The pattern of pleural dissemination, infiltrative growth and the manip-
ulations within the chest cavity during surgery place the entire ipsilateral
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chest wall at high risk for post-surgical relapse, especially at the diaphragm
insertion, the pericardium, mediastinum and bronchial stump. Technically,
hemithoracic radiotherapy is challenging due to various reasons. Firstly, the
size of the volume to be treated is large, and may cover up to six liters.
Secondly, the target lies in close proximity to various organs at risk (OAR)
such as the heart, ipsilateral kidney, liver, remaining lung, esophagus and/or
spinal cord. Thirdly, the thoracic cavity has a complex shape with its cos-
todiaphragmatic recess extending around the liver and the kidney. Previous
publications showed that highly conformal radiotherapy (HCRT) such as in-
tensity modulated radiotherapy (IMRT) or volumetric modulated arc ther-
apy (VMAT) can improve the dose distribution in respect to target coverage
and dose to OAR [7,8]. However to our knowledge there is no clinical study
published that investigated and compared clinical outcome after both radia-
tion techniques. In order to verify if the technical improvements introduced
with IMRT or VMAT have translated into a clinical benefit, we evaluated
the clinical outcome of MPM patients treated with chemotherapy, surgery
and 3DCRT or HCRT at our institution.
1.3 Material and methods
We reviewed the clinical outcome of 39 consecutive patients treated either
with 3DCRT (25 patients) or HCRT (11 IMRT patients and 3 VMAT pa-
tients). Patient staging was established using FDG-PET/CT and/or conven-
tional thoraco-abdominal CT. The patients with clinical stage T1-T3, N0-2,
M0, R0-2 were treated with 3 cycles of preoperative chemotherapy (peme-
trexed and cisplatin) followed by EPP and RT [7]. All histological subtypes
were accepted for RT. Patients were not selected for this review if they had
metastatic disease or a local relapse before the start of RT. The study was
approved by the local ethics committee.
1.3.1 Radiation techniques
The 3DCRT group was treated between 1999 and 2005. These patients were
treated with 25 x 1.8 Gy = 45 Gy to the hemithorax and subsequently, in
a second series, a boost of 7 x 1.8 Gy = 12.6 Gy was given to the incom-
pletely resected area (total dose 57.6 Gy). Dose calculation was performed on
Pinnacle planning system (Philips Medical Systems) for a linear accelerator
(Clinac 2100C, Varian Medical Systems). Details of the treatment technique
have previously been published [7].
HCRT has been used at our institution since 2005 for the treatment of
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MPM patients. Of the 14 patients treated with HCRT, 11 were treated
with conventional static field IMRT and 3 patients with rotational IMRT
(volumetric arc radiotherapy, i.e. Rapid Arc R©in the present series).
IMRT and VMAT plans achieved similar dose distributions [9, 10]. In
the case of HCRT only one series was applied with 26 x 1.75 Gy = 45.5 Gy
delivered to the hemithorax with a simultaneous integrated boost of 26 x 2.15
Gy = 55.9 Gy delivered to the R1/R2 region. Planning and dose calculation
was performed on the Eclipse planning system (Varian Medical Systems, Palo
Alto, CA) for a linear accelerator (Clinac 6EX or Trilogy, Varian Medical
Systems). The treatment technique and dose-volume constraints have been
previously published [7, 9, 11].
1.3.2 Follow-Up and recurrence
Patients were followed up every three to four months with clinical examina-
tions and CT or PET/CT scans. Local tumor progression or recurrence was
defined as an increasing radiographic abnormality within or partially within
the irradiation field. Recurrence adjacent to the field border but not in-field
was defined as marginal miss recurrence. Regional recurrence was defined
as recurrence in close proximity but not within the irradiated field. Tumor
recurrence in the contralateral hemithorax or abdominal cavity was classified
as a distant recurrence [12]. All in-field recurrences were carefully analyzed
by 2 of the authors (JK, PD), in order to assess if they occurred in previ-
ously underdosed areas by comparing the respective diagnostic image with
the radiation therapy treatment plan.
1.3.3 Statistics
All survival endpoints as well as tumor recurrence were measured from the
date of treatment start (neoadjuvant chemotherapy) and were evaluated us-
ing the Kaplan Meier Method. In a subset of the cohort, a matched pair anal-
ysis was performed in order to compare outcome after 3DCRT and HCRT.
For this analysis, the patients were matched for age, preoperative TNM, R
and histology, and sex (except one pair).
1.4 Results
Between 1999 and 2011, 39 patients were treated with neoadjuvant
chemotherapy and EPP followed by RT. All follow up patients were deceased
at the time of this study.
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1.4.1 Matched pair analysis
In the matched pair analysis, 11 HCRT and 11 3DCRT patients were matched
based on tumor staging, resection status, tumor histology, age and gender
(except one pair were the gender was not matched). In each group 3 patients
had a tumor stage T1N0M0 with resection R0 and 8 patients, tumor stage
T2N0M0 with resection R1. Tumor histology was epithelioid for 6 patients
and biphasic for 5 patients in each group. The mean age was 59.6 years and
59.8 years for patient
’
A¨oˆs in the HCRT and 3DCRT group.
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Figure 1.1: Local control for 11 matched modulated radiotherapy (HCRT)
patients and 11 3-dimensional conformal radiotherapy (3DCRT) patients.
The median time to local relapse was increased by 49 % with HCRT in
comparison to 3DCRT from 10.9 ± 5.4 months to 16.2 ± 3.1 months (p =
0.06) as displayed in Figure 1. Three (27.3 %) and eight patients (72.7 %)
had a local relapse after HCRT and 3DCRT respectively. Nine HCRT (81.8
%) and nine 3DCRT (81.8 %) patients developed metastases within a median
time of 18.4 ± 10.7 months and 10.9 ± 8.6 months (p = 0.21). The difference
in disease free survival between HCRT and 3DCRT was not significant (p =
0.72). The median overall survivals were 22.3 ± 15.3 months for HCRT and
21.2 ± 9.2 months for 3DCRT and are displayed in Figure 2 (p = 0.57).
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Figure 1.2: Overall survival for 11 matched modulated radiotherapy (HCRT)
patients and 11 3-dimensional conformal radiotherapy (3DCRT) patients.
1.4.2 Outcome of the entire cohort
Fourteen HCRT and 25 3DCRT patients were treated and reviewed. Patient’s
sex, age, tumor characteristics and resection are displayed on Table 1.1.
The median overall survival was 20.8 ± 14.4 months for the HCRT group,
and 26.9 ± 11.8 months for the 3DCRT group (p = 0.48). In the HCRT
group, 10 patients (71 %) died of progressive disease and 4 patients (29
%) due to intercurrent disease:, one patient died of septic shock, one of
acute myocardial infarction, one of progressive biventricular heart failure
and another patient, who was well and without evidence of disease at two
days before his sudden death, most likely also died due to a cardiac event.
In the 3DCRT group 24 patients (96 %) died of progressive disease and one
of septic shock (4 %).
The local control rates were improved after HCRT (p = 0.30). Four
HCRT patients (28.6 %) suffered from locoregional relapse in comparison to
15 patients (60 %) treated with 3DCRT.
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Characteristic HCRT 3DCRT
n = 14 n = 25
Male 13 22
Female 1 3
Mean age (years) 61 61
Right sidded tumor 9 15
Left sidded tumor 5 10
Tumor histology epithelioid 8 17
Tumor histology biphasic 6 8
Initial tumor stage T1 3 15
Initial tumor stage T2 10 10
Initial tumor stage T3 1 0
Initial nodal stage N0 14 22
Initial nodal stage N1 0 1
Initial nodal stage N2 0 2
Resection R0 4 8
Resection R1 9 15
Table 1.1: Patient demographics and tumor characteristics of 39 patients who
underwent neoadjuvant chemotherapy, extrapleural pneumonectomy and ra-
diotherapy. Abbreviations: HCRT: Highly conformal modulated radiother-
apy, 3DCRT: 3 dimensional conformal radiotherapy
8 1. Clinical outcome for MPM after HCRT
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1.4.3 Analysis of tumor recurrence
For patients treated with HCRT, local relapse occurred in-field in 3 patients
(21.4 %), all within areas that had been treated with doses between 43 Gy to
59 Gy (according to our treatment planning protocol 95 % of the prescribed
45 Gy (=43 Gy) should enclose the target volume, which in this case is the
tumor bed of the hemithorax, Table 1.2) and none in a clearly underdosed
region. One patient (7.1 %) had a marginal miss recurrence at the field border
(13 Gy). In the 3DCRT group, twelve patients (48 %) had in-field recurrences
in regions treated with doses between 30 Gy and 56 Gy (Table 1.3). Notably,
in 16 % of patients treated with 3DCRT (4/25) in-field recurrences occurred
in regions that were covered with doses of only 30 to 43 Gy, instead of the
prescribed > 45 Gy. One patient (4.0 %) had a marginal miss recurrence (18
Gy). In one patient with a regional recurrence (4.0 %) the delivered dose
was not possible to define because no diagnostic CT was available. In one
patient (4.0 %) the site of recurrence could not be determined because of
missing radiographs during follow-up
10 1. Clinical outcome for MPM after HCRT
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Distant recurrences occurred in ten patients (71.4 %) treated with HCRT
and in twenty 3DCRT patients (80 %). The median time to distant metas-
tases was 18.4 ± 10.7 months in HCRT group and 16.7 ± 7.7 months in
3DCRT group (p = 0.7). In the HCRT group, distant metastases involved
only the contralateral chest in three patients (30 %) and only the abdominal
cavity in three patients (30 %). Both sites were affected by distant metastases
in four further patients (40 %).
1.5 Discussion
We demonstrate in a retrospective analysis of patients with MPM and treated
at our institution with trimodality therapy that the use of postoperative
highly conformal radiation techniques (HCRT) reduces local recurrence in
comparison to 3DCRT. A recurrence analysis showed that in the case of
3DCRT 4 of 25 patients (16 %) had a local recurrence in regions that were
clearly underdosed according to current radiation protocols (doses > 45 Gy
are recommended, e.g. SAKK 17/04) in contrast to 0 % of patients treated
with HCRT. This supports the hypothesis that HCRT should improve local
control in comparison to 3DCRT by improving target volume coverage. In
our study patients treated with HCRT showed a tendency for improved pro-
gression free survival and local relapse free survival but did not benefit in
terms of overall survival due to the high rates of distant relapses.
Local control is important in patients with MPM for symptom control,
but also because some patients might benefit in terms of improved overall
survival. Better local control after HCRT did not translate into improved
overall survival in our patient series. Remarkably, the rate of death due to
intercurrent disease, most often cardiac events, was higher after HCRT (29 %)
in comparison to 3DCRT (4 %). Since cardiac sparing is rather improved with
HCRT the most likely explanation for this difference is patient selection. The
urgent research question, if postoperative radiotherapy impacts on overall
survival after EPP, is addressed by a randomized study currently conducted
in Switzerland, SAKK 1704. Patient accrual for this study was terminated
in 2012 and the results are awaited.
Even after trimodality treatment local recurrence remains high in some
patient series. In a retrospective series of 49 patients treated with 3D-
conformal RT after EPP and chemotherapy 67 % of all recurrences included
the ipsilateral hemithorax and 25 % of all recurrences were local only [12].
Therefore improvement of radiotherapy is mandatory. In recent years radio-
therapy has made enormous technical advances. More sophisticated highly
conformal radiation techniques (HCRT) such as IMRT or rotational RT
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(VMAT) have become available and substituted for the older 3DCRT tech-
nique. The use of HCRT enables improvement in the dose distribution and
target volume coverage. This is because with HCRT even complex target
volumes such as the tumor bed of the costodiaphragmatic recess or the peri-
cardium can be treated without or with little dose compromise and at the
same time with optimal sparing of the normal tissue due to a steeper dose
fall-off. Thus, the use of HCRT should intuitively improve treatment out-
come in terms of local tumor control. Our data suggest indeed, that the use
of HCRT bears considerable potential to improve on hemi-thoracic tumor
control rates most likely due to improved target volume coverage.
The poor local control rates and high rates of in-field recurrences fol-
lowing 3DCRT in our cohort may be due to suboptimal dose coverage or
the restriction of the target volume to avoid critical organs, both limitations
inherent to the technique. After 3DCRT 4/24 (16.6 %) in-field recurrences
occurred in regions covered with only 30-43 Gy. In the case of 3DCRT mixed
beams of photons and electrons were used to optimize dose coverage. The
match of these beams often causes cold and hot spots of dose coverage. Poor
matching during daily treatment can result in > 20 % dose inhomogeneity
in the junction area [7]. In addition, as the spinal cord is blocked when the
tolerance dose of 45 Gy is reached, insufficient dose delivery to parts of the
mediastinum has been observed, resulting in underdosage to the tumor bed
[7].
Favorable tumor control after IMRT as part of a trimodality therapy has
previously been reported by Rice et al. [13]. The median overall survival
of their 61 patients treated was 14.2 months with a locoregional recurrence
rate of 13 % and only 5 % local in-field recurrences reported. The median
dose prescribed was only 45 Gy, and half of all patients received doses even
less than 45 Gy. The reason for the comparatively higher local control rate
reported by Rice et al. in comparison to our study remains unclear. It may
be explained by patient selection and the comparatively short median overall
survival of 14.2 months in comparison to 20.8 months in the present series
and by the retrospective study design. The shorter median overall survival
reported by Rice et al. could be caused by more advanced tumor stages (40
T3, 8 T4, 26 N2), more aggressive subtypes (14 biphasic, 4 sarcomatoid) and
the fact that neoadjuvant chemotherapy was not routinely administered.
With regard to toxicity the major dose limiting organ for postoperative
radiotherapy of MPM is the contralateral lung. Lung complications such
as radiation pneumonitis are likely to be higher with multi-field techniques
such as IMRT or VMAT in comparison to 3DCRT, where opposed beams
from 0 and 180 degrees are usually used, thereby optimally sparing the con-
tralateral lung. With regard to dose escalation and lung sparing surgery,
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protons might prove superior to IMRT/VMAT. Severe complications of the
lung with grade 4 and 5 pneumonitis after IMRT have been reported [7,12].
Since then, special attention to the contralateral lung dose has been given
during the treatment planning process and pneumonitis rates should be lower
today. Intuitively, the use of HCRT should reduce toxicity and complication
probabilities of esophagus, heart, liver and kidney, however no data with
regard to these toxicity endpoints comparing both treatment techniques are
available.
In recent years, the need for extensive surgery has been questioned, and
less radical surgery has been advocated such as pleurectomy/decortication.
In the context of reduced surgery, the anatomical situation makes it diffi-
cult for RT to be applied to the entire pleural space, however, it can still be
considered as a targeted local postoperative option in case of incomplete re-
section. Future clinical studies are required to define the role of radiotherapy
in combination with lung sparing surgery.
1.6 Conclusions
In summary, the use of HCRT for treatment of patients with MPM after EPP
is likely to improve local control rates. The local control improvement did
not improve the overall survival due to the high rates of distant relapses in
this series. Further improvement of trimodal or systemic therapy is required
to tackle the high risk of distant recurrences.
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2 1. Hierarchical enhanced non-rigid registration
1.1 Abstract
Target volumes change during fractionated radiotherapy (RT). We inves-
tigate a tool based on the Hierarchical Enhanced Registration Algorithm
(HERA) to project a 3D-segmentation set of the prostate into the subse-
quent imaging sets at any time point during RT by using intensity-based
image registration techniques.
Sequential CT sets during RT at 15, 30, 45 and 60 Gy of two patients
were used. Five expert clinicians outlined the prostate in a blinded fash-
ion, defining intra-observer and inter-observer variability on a set of 35 and
25 scans, respectively. The observer variability and positioning for manual
correction was compared to both affine and elastic image registration-based
contour propagation.
The overall mean-error of the registration-based correction of the planning
target volume was comparable to the inter-observer variability of manual
target volume definition. The correction by affine image fusion was inferior
to the results of elastic registration. The maximal deviation for the inter-
observer segmentation was 15.4 mm, 10.5 mm for the affine and 8.0 mm
for the elastic registration. The mean inter-observer variability was 1.5 (±
1.4) mm, 2.8 (± 2.3) mm for the affine and 2.2 (± 1.9) mm for the elastic
registration.
Intensity-based elastic registration of deformable anatomical structures
with HERA is suitable for the assessment of changes of prostate volumes for
the purpose of target propagation and adaptive radiotherapy.
1.2 Introduction
External beam radiotherapy of the prostate is generally performed over a
larger number of fractions. Over this period, the volumes of the rectum
and bladder can fluctuate causing displacement and may contribute to the
deformation of the target volumes, as well. Therefore, anatomical and ge-
ometrical uncertainties must be taken into account by the planning target
volume (PTV). The spatial plasticity of the prostate during the course of
RT has been well documented, and the volume of the prostate may slightly
increase during the first days of RT and shrink during the following weeks
[1, 2]. In order to keep PTV margins minimal, daily target positioning veri-
fication before treatment can be beneficial [3]. Several techniques have been
investigated to account for the inter-treatment positioning variability of the
prostate. Before high-resolution in-room fluoroscopy or 3D-on-board imag-
ing systems became available, the localization of the prostate mostly relied
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on remote anatomical bony markers. Endorectal spacers help to predict the
position of the prostate and could reduce internal target volume (ITV) mar-
gins [4]. Direct prostate localization is achieved with fiducial markers in the
prostate [5, 6]. Other positioning systems rely on ultrasound technology or
transponders [7, 8]. All these approaches, however, neglect the plasticity of
the target structures and volumes over the treatment time.
Onboard CTs during RT provide a novel opportunity to redefine the vol-
ume of the prostate on a daily basis and if necessary, adapt the CTV. How-
ever, the reliability of CT-based prostate localization and volume assessment
may be reduced by technical limitations, such as the typical low contrast soft
tissue differentiation of the common on-board CT imaging systems, interfer-
ing with re-segmentation and automated target volume reconstruction.
In the present work we investigate the possibility of using image registra-
tion techniques as a tool for target volume propagation. Image registration
is the process of transforming the different sets of data onto one coordi-
nate system, such that the scene or the objects pictured from different views
and/or at different time points are brought into alignment. Considering that
the physician can make a detailed planning and contouring of the prostate
onto an initial CT scan of a patient, we registered it to all the subsequent
CTs acquired during the RT. By using non-rigid image registration tech-
niques such as the Hierarchical Enhanced Registration Algorithm (HERA)
[8], we studied the performance of both affine and non-rigid transforma-
tions to estimate the spatial changes and to compensate for the plasticity of
the pelvic structures. The information from the positioning changes of the
pelvis is applied to the prostate clinical target volume (CTV), allowing pre-
cise prostate localization during potentially each single treatment sessions.
The ability of the physicians to manually define the prostate volume for the
purpose of adaptive radiotherapy is compared to the performance of the pro-
posed automated computer-based CTV registration. Routine adaptation of
the prostate volume and on-line re-planning to account for volume changes
during radiotherapy has not been introduced in routine treatment yet. One
major requirement in implementation of adaptive image guided radiotherapy
will rely on optimal iterative target volume assessment procedure. Using a
method based on ray casting, hierarchical image registration , and manual
segmentation is a novel approach in the context of adaptive radiotherapy.
We hypothesize that the automated registration with HERA will improve
the contouring of the prostate and eventually allow minimizing PTV mar-
gins for the purpose of adaptive radiotherapy, especially posteriorly avoiding
underdosing the posterior lobes of the prostate.
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1.3 Materails and Methods
1.3.1 Patient characteristics and CT acquisition
Sequential CTs were obtained from two prostate-cancer patients undergoing
external beam radiotherapy. Patients were scanned and treated in a supine
position with a rectal balloon with 40 cm3 of air [4]. CTs were obtained
before starting treatment and at 15 Gy, 30 Gy and 45 Gy for two patients,
and, additionally, 60 Gy for one patient. All CTs have been performed on a
helical single slice CT scanner. The slice thickness of the CT images was 5
mm for both patients. The in-plane resolution was 512 x 512 pixels of 0.9766
x 0.9766 mm2 for the first patients, and 512 x 512 pixels of 0.8301 x 0.8301
mm2 for the second patient.
1.3.2 Prostate contouring - inter-observer and
intra-observer segmentation variability
The inter-observer variability of the manual prostate segmentation was de-
fined by a group of five expert clinicians that, in a blinded fashion, manually
contoured repeatedly the prostate in all 7 available CTs (0 Gy, 15 Gy, 30
Gy for two patients and 60 Gy for one patient). The manual segmentation
was performed using Eclipse treatment planning system (Varian Medical Sys-
tems, Palo Alto, CA), and saved as DICOM-RT to be used in subsequent
analysis. The long-term intra-observer variability was investigated by asking
the same doctors to repeat the prostate segmentation in the available CT
data. The average time interval between the delineation of the first and the
second set of contours was about 6 months, in a blinded fashion. For both
patients, the segmentation was done for the entire time-series of CT acquisi-
tions (7 images) resulting in 35 CT sets for the inter-observer analysis. For
the intra-observer analysis, the segmentation was repeated for the acquisition
prior to the RT resulting in a set of 20 CTs.
1.3.3 Distance-based metrics
Each CT image had a series of 5 manual segmentations of the prostate, each
of them furnished a set of 2D axial contour points defined on subsequent
slices of the acquisition. The average center of mass of the prostate (CMP)
was estimated from all the contour points of the 5 segmentations and each
segmentation was reconstructed by using a simple tessellation procedure of
the originally defined points. Then, the CMP was used as source point to
radially cast 2048 rays, uniformly distributed using a constant angular step in
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both elevation 0˚ < θ < 180˚ and azimuth 0˚ < φ < 360˚ directions. The average
spatial location of the 5 intersection points between the segmented surfaces
and each ray casted from the CMP was then used to estimate an average
segmentation surface. At the same time, these intersection points, along each
casted ray, define an estimate of the local inter-observer variability (within
the analysed CT image). By putting together all these local estimates, we
expressed globally the inter-observer segmentation variability in terms of
standard deviations of contour displacements within the same CT image as
delineated by the group of 5 clinicians.
In a similar local manner, the long-term intra-observer variability was
expressed in terms of standard deviation of the contour displacements distri-
bution estimated from the long-term repeated manual segmentations of the
five clinicians on the two available CTs prior RT.
1.3.4 Image registration and contour propagation
HERA was used to estimate and to correct for the plasticity of the pelvic
structures between subsequent CT scans [8]. HERA optimized an affine
transformation (displacement, rotation, skew and scaling) and an elastic de-
formation field between the initial CT scan (prior to RT) and each subsequent
CT scan (during RT) of each patient. These transformations (affine and elas-
tic) were used eventually to propagate the prostate contour as defined on the
initial CT scan of each patient, prior to RT. The registration procedure used
image intensity cross-correlation as similarity measure, as all images were
acquired in the same modality (i.e. CT). In addition, to limit the influence
of out of interest pelvic tissues and structures, we restricted the registration
process to the prostate surrounding region.
The propagated contours were characterized by using the same ray-
casting strategy as for the evaluation of the intra- and inter-observer manual
segmentation variability.
1.3.5 Evaluation of the contour propagation
effectiveness
To evaluate the precision of image registration as a propagation tool, we
compared the propagated contours of the prostate with the segmentations
obtained manually. We used different measures to locally describe and quan-
tify the precision of the registration for each of the 5 CT data acquired during
the RT.
In a first step, the registration-based contour propagation was compared
to the inter-observer variability of the prostate segmentation. Therefore,
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a two-tailed Student t-test was used on the null hypothesis that the mean
(average) of the propagated contours is inside the confidence interval of the
mean of the manually segmented contours against the alternative hypothesis
that the mean of the propagated contours is outside this confidence interval.
In a second step, the registration-based contour propagation was com-
pared to the intra-observer variability. Having the CT data segmented twice
by each doctor, one can compare the two populations of contour deviations
originating from the same person - in one case, the contours have been gen-
erated by the same person on the same image, and in the other case, the
contours have been generated by the same person on two different images
and propagated over. Therefore, we compared the deviations in contouring
the same image with deviations in contouring different images that are af-
terwards registered. If the first population describes only the reproducibility
in contouring of the observers, the second population represents a complex
variability that accumulates the reproducibility in contouring together with
the registration/propagation error.
For all tests performed, the CT done at 0 Gy, prior to RT, was chosen
as the floating image. The following CTs were considered as reference. As
such, the initial contours are always propagated onto the following acquired
images.
In all these statistical tests, each population was consisted of 2048 sets,
each consisting of 5 points. A statistical t-test was performed locally on each
sets of point, along each casted ray (the tests were performed 2048 times).
For all tests, a p-value smaller than 0.05 was accepted as significant.
1.4 Results
1.4.1 Contour propagation versus inter-observer
variability
First, we evaluated the performance of the propagation of the planning con-
tours against the inter-observer variability of the prostate segmentation. Ta-
ble 1.1 describes the inter-observer variability (the 1st row), together with the
registration error of contour propagation while using the affine registration
(the 2nd row), and while using the elastic registration (the 3rd row). Ta-
ble 1.1 summarises the average of the descriptive statistics for the differences
from the mean prostate contour: the mean, the standard deviation, and the
maximal distance. The mean deviation was increased by 1.24 mm with the
affine registration and 0.64 mm with the elastic registration in comparison to
the segmented registration. But the maximum registration was reduced by
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1.38 mm (respectively 2.76 mm) with the affine (respectively elastic) registra-
tion. The mean and maximum deviation was the largest in the Y-direction
(superior-inferior direction) for affine and elastic registration due to the CT
resolution in the Y-direction (5 mm). In the anterior-posterior direction, the
mean deviation was small, bellow 1 mm for the manual, affine and elastic
registrations. Nevertheless, the maximal deviation could be reduced by 3
mm with the affine registration and 3.7 mm with the elastic registration.
8 1. Hierarchical enhanced non-rigid registration
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Fig. 1.1 depicts a box-plot for the local inter- and intra-observer variabil-
ity distribution (along the 2048 rays) together with the contour propagation
errors (by affine or elastic transformations) from one set of images that were
thereafter registered. The inter- and intra-observer segmentation variabil-
ity is represented on both images: the reference image (a follow-up image)
and the floating image (the planning or initial image). The results showed a
slight increase of the median deviation with the affine and elastic registration
in comparison with the manual segmentation. A decrease of the maximum
deviation is therefore achieved with the affine and elastic registration. The
intra-observer deviation could be reduced by more than 3 mm with the affine
registration and by more than 5 mm with the elastic registration. Fig. 1.2
depicts an example of distribution of the p-values over the entire surface of
the prostate. The p-value represents the goodness of fit of two populations
of contours formed on one side by the manual segmentations of the prostate
in the currently analyzed image, and, on the other side, the affine and elastic
segmentations propagated from the planning CT. The values p < 0.05 indi-
cate a failure to propagate the planning contours, which is equivalent with
a rejection of the null hypothesis that stated that the two populations are
similar. In the present case, 95.5 % (respectively 97.4 %) of the 2048 sets of
points had a p > 0.05 for the affine (elastic) registration.
Fig. 1.3 illustrates for the same set of images the distribution of various
statistics over the segmented surface of the prostate. The inter-observer
variability in the segmentation of the prostate is the largest in the superior
part of the prostate. In this region, the standard deviation was larger than 1.8
mm in the reference images and larger than 2.5 mm on the floating images.
The same variability was observed for the left part of the prostate. However,
on the right side, the standard deviation was the smallest, under 0.6 mm.
The 3rd and 4th rows depict the spatial distribution of the p-values of the
contour propagation when using the affine and the elastic registration. The
white patches represent those regions where the propagation of the planning
contours failed (p < 0.05). These regions locate in the anterior direction for
the affine and elastic registration and on the right direction for the affine
registration. In these regions the inter-observer variability is small, less than
1 mm. Small mis-registrations had major influence on the statistical tests,
were p values smaller than 0.05 were observed.
1.4.2 Contour propagation versus intra-observer
variability
A next stage of our study was to examine the performance of the planning
contours’ propagation against the intra-observer variability. By using the
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Figure 1.1: Deviation of inter- intra-individual segmentation and the regis-
tration errors. Summary of the intra- and inter-observer variability of the
segmentation and the propagation errors for the target CT performed at
30 Gy. All the deviations are given in absolute values. The box-plots vi-
sualize the local inter- and intra-observer variability distribution (along the
2048 rays) together with the contour propagation errors (by affine or elas-
tic transformations) from one set of images that were thereafter registered.
The inter- and intra-observer segmentation variability is represented on both
images: the reference image (a follow-up image, denoted by ref ) and the
floating image (the planning or initial image, denoted by flt).
same technique of showing the distribution of various statistics over the seg-
mented surface of the prostate, Fig. 1.4 depicts the spatial distribution of
the intra-observer variability over the reconstructed average surfaces of both
planning and target CT on the first two rows. The intra-observer variability
is large in the superior and inferior part of the prostate, with a standard
deviation up to 4 mm. In the other regions the standard deviation is below
2.5 mm. The 3rd and 4th rows of Fig. 1.4 show the spatial distribution of
the p-values on the prostate surface. The registrations are very good in the
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Figure 1.2: Distribution of the p-values over the entire surface (2048 points)
of the prostate whilst evaluating the performance of contour propagation
against the inter-observer variability of manual segmentation. The propa-
gation of the planning CT was performed for the CT scan at 30 Gy. The
p-values < 0.05 indicate significant differences and therefore propagation fail-
ure.
superior and inferior part of the prostate while in the right, left and pos-
terior direction, the propagation failed (the white patches with p < 0.05).
Here again, the registration failed in regions were intra-observer variability
is smaller than 1mm.
1.5 Discussion
Inter-treatment target volume variability is a well recognized source of error
in external beam radiotherapy [9]. Repeated 2D or 3D-imaging prior to dose
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delivery has been used to ascertain target coverage and to spare neighbouring
structures [10]. Currently clinical standards use rigid positioning verification
approaches, basing mostly on 2D, and more recently on 3D structure match-
ing techniques [11]. Adaptive treatment taking structure deformation into
account improves dose distribution of photon-based treatments [12].
In the present study we show that, by using a registration algorithm as
a propagation tool, an automated 3D computer-based target volume adap-
tation over a prolonged treatment compares favorably with expert-derived
target reassessment for the purpose of adaptive planning. Target volume
propagation using deformable imaging registration for adaptive RT bears
several potential advantages, especially, the possibility to reduce the inter-
nal target margin to close to zero [13]. Imaging systems for target position
verification systems, such the Calypso System (Calypso Medical Technolo-
gies, Seattle, USA) or the ExacTracTM(BrainLAB, Feldkirchen, Germany),
allows reducing the irradiated target volume margins to 1 mm if imaging of
the prostate localization is used every 15 seconds [14]. In the case of high
dose applications, for example prostate, saving millimeters in the posterior
margin could be clinically beneficial for the rectum , especially at dose levels
exceeding 75 Gy [15]. The reduction of the posterior margin of the planning
target volume results in a reduction of the dose applied to the rectum and
makes dose escalation feasible. On the anterior direction, a reduction of the
margin would also reduce the dose to the pubic symphysis, which is in close
proximity to the PTV.
The inter- and intra-observer deviations were greater or similar to the
variance of the population formed by deviations in contouring for the elastic
region in a very large portion of the prostate. Furthermore, elastic registra-
tion based contour propagation performed better than manual re-contouring
of the prostate in all three spatial directions in respect to the maximal devi-
ation. The maximal deviation could be reduced using the elastic registration
in comparison to the inter-observer variability. The largest deviation was
observed in the superior-inferior direction. This is probably due to the CT
resolution in the superior-inferior direction, which was 5 mm in compari-
son to 0.8301 mm and 0.9766 mm for the two patients in the left-right and
anterior-posterior directions. By reducing the slice thickness, a decrease of
the mean and maximal deviation could be achieved for the affine and elastic
registration.
The affine and rigid registration failed in regions were inter and intra-
observer variability was small (<1 mm). In these regions the standard de-
viation of the affine and rigid registration was larger by less than 0.3 mm
(Table 1). This difference was significant but not clinically relevant since we
are bellow the set-up accuracy.
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The elastic registration performed better than the affine adjustment. This
improvement will have a direct impact when on-line re-optimization is used
[9]. Indeed, an improvement of the accuracy of the registration will have a
direct impact on the margins for the target and therefore, on the dose to the
organ at risks.
1.6 Conclusion
HERA-based non-rigid prostate volume reassessment using repetitive CT
during radiotherapy for the purpose of position verification, target volume
adjustment and on-line plane re-optimization allows the clinician to minimize
PTV margins. Elastic target volume propagation is a feasible and attractive
strategy which merits clinical implementation in the treatment workflow and
verification of its utility for the purpose of adaptive RT planning.
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Figure 1.3: Contour propagation versus inter-observer variability. The sur-
face distribution of the inter-observer variability, defined as standard devi-
ation of the segmentations done by 5 doctors at 30 Gy (the first row) and
on the floating data at the time prior to treatment (the second row). The
distance are represented in mm. The distribution of the p-values onto the
prostate after affine (the third row) and elastic (the fourth row). The white
parts are marking the regions where the contour propagation failed.
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Figure 1.4: Contour propagation versus intra-observer variability. The first
two rows depict the intra-observer variability onto the currently analyzed
data (CT performed after 30 Gy) and onto the planning data (CT per-
formed). The following two rows depict the p-values distributed on the av-
erage surface of the prostate. The white parts represent the regions where
the standard deviations of the intra-observer variability is smaller than the
propagated variability.
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